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1. INTRODUCTION AND BACKGROUND FOR THE PROPOSED RESEARCH 
 
1.1. Epidemiology of prostate cancer 
 
Prostate cancer (PCa) is the most common cancer among male population in Western world. 
Annually, there are more than 180.000 new cases of PCa in the United States, with more than 
26.000 deaths from PCa (1). In Canada, although incidence and mortality rates are declining, 
PCa is the most common male malignancy, and third leading cause of cancer-related death, 
only after lung and colorectal cancer. In 2015, 24.000 Canadian men were diagnosed with PCa, 
and more than 4.000 died from the disease. Moreover, one in eight Canadian men will be 
diagnosed with PCa in their lifetime (2). In Croatia, epidemiological situation is similar. 
According to last available National Cancer Registry data for 2014, PCa is the second most 
common cancer in Croatian men, with more than 1.700 new cases recorded in 2014. In the 
same year, 750 men died from this malignancy, making PCa the third largest cause of cancer-
related mortality in Croatia, after lung and colorectal cancer. PCa incidence in last few years is 
stable in Croatia, but the mortality is slowly increasing (3). 
The wide-spread adoption of prostate-specific antigen (PSA) screening in US occurred in the 
1990s resulted in increasing incidence and decreasing mortality rates from PCa (4). However, 
the dispute over role of PSA screening has been ongoing since two PSA-screening trials 
reported conflicting results: European Trial (5) revealed survival benefit associated with PSA-
screening while US trial (6) found no survival difference between PSA screened and not 
screened men leading to US Preventive Services Task Force (USPSTF) recommendation 
discouraging PSA screening for asymptomatic men (7). This recommendation caused 
approximately 5-10% decline in PSA screening rates among US man older than 50 years, 
however, still large proportion of men continues to be screened, especially in age group of older 
than 75, despite having high-risk other-cause mortality where no PSA screening benefit was 
seen even in European trial (8).        
Despite numerous limitation of PSA screening, such as high false-positivity rates and lack of 
specificity, PSA remains the cornerstone for early detection of PCa. Consequentially, over 80% 
of new PCa cases in US are diagnosed in early stage where the tumor is confined to the prostate, 
resulting in 5-year PCa-specific survival approaching 100% (9). However, the natural history 
of PCa is very variable, covering the entire spectrum from slowly progressing disease to 
aggressive, treatment-resistant disease, with rapid onset of metastasis and PCa-related death 
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underlying our inability to distinguish between indolent and aggressive disease based only on 
PSA measurement (10).  
 
1.2. Risk stratification and management options in localized PCa  
 
Localised PCa is stratified into low, intermediate and high risk categories based on classical 
factors, such as clinical T-stage, biopsy Gleason score and initial serum PSA, as these 
parameters predict for PSA-relapse, metastasis and prostate-cancer-specific mortality (11,12). 
Clinical Tumor-Node-Metastasis (TNM) staging system for prostate cancer according to 
American Joint Committee on Cancer (AJCC) is presented in Table 1 (13).  
These clinical factors are the most widely used and form the basis of National Comprehensive 
Cancer Network (NCCN) risk classification, the landmark staging system for PCa (14). NCCN 
criteria recently adopted new risk categories: very low risk and very high risk, acknowledging 
these clinical entities have distinctly different prognosis (15).  
The utility of NCCN risk group classification has been externally validated by D’Amico et al. 
who demonstrated this risk classification system predicted time to PCa-specific mortality after 
primary surgery or radiotherapy (16). Contemporary NCCN risk classification for prostate 
cancer is presented in Table 2.        
 
Table 1. Clinical TNM classification for prostate cancer (American Joint Committee on cancer, 
version 7) 
Primary tumor (T)  
Tx Primary tumor cannot be assesses  
T0 No evidence of primary tumor  
T1 Clinically inapparent tumor neither palpable nor visible by 
imaging   
T1a Tumor incidental histologic finding in 5% or less of tissue 
resected  
T1b Tumor incidental histologic finding in more than 5% of 
tissue resected 
T1c Tumor identified by needle biopsy (e.g. because of elevated 
PSA) 
T2 Tumor confined within the prostate*  
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T2a Tumor involves one-half of 1 lobe or less 
T2b Tumor involves more than one-half of 1 lobe but not both 
lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through prostatic capsule**  
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invading seminal vesicle(s) 
T4 Tumor fixed or invades adjacent structures other than 
seminal vesicles (eg, bladder, levator muscles, and/or pelvic 
wall) 
Regional lymph nodes (N)  
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Distant metastasis (M)*  
M0 No distant metastasis 
M1 Distant metastasis 
M1a Nonregional lymph nodes(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease   
*Tumor found in one of both lobes by the needle biopsy, but is not palpable or reliably visible 
by imaging, is classified as T1c.    
**Invasion into the prostatic apex or into (but not beyond) the prostatic capsule, is not classified 
as T3, but as T2. 
***When more than one site of metastasis is present, the most advanced category is used.  
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Table 2. NCCN risk classification (NCCN=National Comprehensive Cancer Network), 
modified from ref (14).  
 
Very-low risk Low risk Intermediate risk High risk Very high-risk 
T1c 
and 
GS ≤6 
and PSA <10 
and fewer than 3 
biopsy cores 
positive  
and 
≤50% cancer in 
each core 
T1-T2a 
and 
GS 2–6 
and 
PSA ≤10 
not very low-risk 
T2b or T2c 
and/or 
GS 7 
and/or 
PSA >10–20 
not low-risk 
T3a 
or 
PSA >20 
or 
GS 8–10 
not very high risk 
T3b-4 
 
 
In a current practice, majority of men with PSA-detected PCa ultimately undergo definitive 
management with local therapy – either radical prostatectomy or radiotherapy with or without 
androgen deprivation therapy. More precisely, surgical approach as primary treatment modality 
is increasingly utilised across patients in intermediate and high risk groups, while active 
surveillance as approach is rapidly gaining more acceptance and becoming standard in low risk 
group (17). This is especially true for patients with low risk prostate cancer with T1c disease, 
≤3 positive biopsy cores, PSA <10 ng/ml and Gleason score 6, who are considered as best 
candidates for active surveillance program according to recent guidelines (18). Patients with 
intermediate-risk, high-risk or aggressive, locally advanced prostate cancer have a number of 
options for primary local treatment, including radical prostatectomy with pelvic 
lymphadenectomy, dose escalated image guided radiotherapy and brachytherapy (either using 
low- or high-dose rate modality), with differential outcomes (19).  
However, the optimal management of PCa remains controversial as a result of long natural 
history of disease, the diversity of available treatments and lack of high quality data guiding 
the treatment choice.  
External beam radiotherapy (EBRT), along with surgery, constitutes cornerstone of the primary 
treatment modality for patients with localized PCa. EBRT implies use of ionizing radiation to 
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kill cancer. Specifically, high energy megavoltage X-rays generated in linear accelerator are 
being used to treat PCa. EBRT is more often used in patients with high(er) risk features and in 
those with locally advanced disease where is combined with androgen deprivation therapy.  
 
 
1.3. Evolving role of radiotherapy technique and delivery for prostate cancer 
treatment  
 
Numerous advances have occurred in the field of radiotherapy for prostate cancer in last 30 
years. Adoption of information technology and engineering solutions in this field allowed fast 
development. New planning software, introduction of planning based on CT and MRI imaging 
gave rise to advent of 3D conformal radiotherapy, which made possible to escalate the dose to 
the prostate and simultaneously minimize the dose to the organs-at-risk (20).   
Conventional radiotherapy fractionation for radical treatment of PCa before the era of dose 
escalation ranged between 66 Gy and 70 Gy, given in 2 Gy fractions. Treatment volumes were 
treated using four rectangular fields with margins around prostate of 1.5 cm (21,22). Technical 
abilities at that time precluded conformal shaping of the treatment beams. However, in late 
1980s, technological advances in radiotherapy planning software and linac hardware allowed 
major breakthrough: 3D conformal radiotherapy where the beams were shaped according to 
individual patient anatomy and target volume. This treatment technique usually involves the 
utilization of 5-6 field arrangements with maximal shielding and allows dose escalation to the 
prostate beyond 70 Gy, with margins of 1 cm around prostate. With increased number of beams 
used, reduced margins as the consequence of improved precision and maximized shielding, the 
rectal and bladder dose were significantly reduced which gave rise to safe dose escalation to 
the prostate (23).     
Next step in development of radiotherapy technique is advent of Intensity Modulated 
Radiotherapy (IMRT) in early 1990s which since then has been rapidly assimilated into regular 
clinical practice.  
Briefly, IMRT is advanced form of conformal radiotherapy for delivering EBRT to highly 
conformed treatment volumes. In IMRT process each beam is being segmented into multiple 
beamlets, where each beamlet has individually controlled radiation intensity. This enables the 
high dose volume to be more appropriately shaped around the target volume further reducing 
the dose to normal tissue. Moreover, IMRT involves inverse planning, where dose constraints 
for critical organs and target doses along with hierarchy of organs-at-risk sparing are predefined 
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and the plan is produced and optimized to best match all input criteria. IMRT was made 
possible by the use of a multileaf collimator and advanced treatment planning calculation 
algorithms that optimize its position (20). Nowadays, majority of North American radiotherapy 
centers treating PCa use IMRT technique. This technique is currently recommended over 3D 
conformal radiotherapy for the radical treatment of localized PCa in which an escalated 
radiation dose (>70 Gy) is required (24). However, the hypothesis that IMRT technique would 
lead to better patient-reported outcomes (and better quality of life) as opposed to 3D conformal 
technique has never been tested in a randomized trial. On further note, analysis of dose-
escalated arm of RTOG 0126 trial showed no difference in relevant patient-reported outcomes 
(bowel, bladder, sexual) between patients treated with IMRT when compared to those treated 
with 3D conformal technique (25).   
Further work was done in the field of image-guidance technologies for precise delivery of daily 
radiation treatments. For this purpose intraprostatic fiducial markers use and on-board  imaging 
using cone-beam CT or MRI allowed to monitor and correct for daily prostate motion and 
enhanced precision in modern radiotherapy that improved cure rates in prostate cancer while 
minimizing toxicity (26,27).  
 
 
1.4. Radiotherapy dose considerations  
  
First evidence of a dose-response above 60 Gy in localized PCa was obtained by Zelefsky who 
ascertained benefits of increasing radiotherapy dose in terms of PSA nadir and biochemical 
control. He prospectively increased the dose to the prostate from 64.8 Gy to 81 Gy and the 
patients with intermediate- and high risk PCa benefited the most from this dose escalation (28). 
Moving forward, in the same institution (MSKCC), with accruing more patients on dose 
escalated protocols, authors have observed improvement in local control, distant metastasis, 
and prostate cancer specific mortality (29).  
Although optimal EBRT dose for treating PCa has not yet been defined, six large randomised 
trials of dose escalation in PCa have consistently showed that increase in the radiotherapy dose 
resulted in improved biochemical control, and in one trial metastasis-free survival and PCa-
related survival. Simultaneously, there was also an increase in late toxicities observed. 
Summary of details and findings from dose escalation trials are presented in Table 3.  
  
7 
 
In a trial by Pollack et al. patients were randomized to 78 Gy or 70 Gy and better biochemical 
control and a diminished rate of distant metastasis and CaP deaths were found in higher dose 
arm. At detailed look, patients younger than 70 years with PSA of more than 10 ng/ml have 
benefited the most from dose escalation (30–33). Improvement in biochemical relapse-free 
survival ranging from 10%-25% was the common finding across all trials (34–39).  
In the most recent report of RTOG 0126, the largest study addressing the benefit of dose 
escalation, where 1,500 patients with intermediate-risk CaP were randomised to 79.2 vs. 70.2 
Gy, 7-year OS was similar between both cohorts (HR 0.98, 95%CI[0.79-1.21]) although in 
dose escalated arm were less metastatic events observed (40). In the dose escalated arm, only 
3% of prostate cancer-specific mortality was observed underlying relevance of competing 
causes of death in dose escalation trials where the overall survival is expected endpoint. Careful 
patient selection is needed for dose escalation. Probably younger patients with high-risk disease 
are those most likely to experience benefits of treatment with higher radiation doses (33).  
 
 
Table 3. Overview of radiotherapy dose-escalation trials for localized prostate cancer 
 
Trial N Patients RT dose 
levels 
ADT Median 
follow-
up 
Main finding 
(control 
group vs dose 
escalated 
group) 
Toxicity 
(control group vs 
dose escalated 
group) 
Reference 
 
 
 
 
 
MRC 
RT01 
(UK) 
843 IR: 37% 
HR: 43% 
64 Gy in 32 
fractions vs 
74 Gy in 37 
fractions 
All pts 
received 
neo-
adjuvant 
ADT for 
3-6 
months 
10 years 10-year BPFS 
43% vs 55%, 
p=0.0003 
10-year OS 
71% for both 
groups 
(p=0.96) 
5-year grade ≥2 late 
GU 8% vs 11% 
(p=0.056) 
grade ≥2 late GI 
24% vs 33% 
(p=0.055) 
Dearnaley 2007 (41) 
Dearnaley 2014 (38) 
MDACC 
93-002 
301 IR: 46% 
HR: 34% 
70 Gy in 35 
fractions vs 
78 Gy in 39 
fractions 
No 8.7 years 8-year FFBF 
59% vs 78% 
(p=0.004) 
8-year FFDM 
95%  
vs 99%, 
p=0.059 
8-year OS 
78% vs 79%, 
p=0.315 
Late GI grade ≥2 
13% vs 26%, 
p=0.013 
Late GU grade ≥2 
8% vs 13%, p=NS 
Pollack 2002 (31) 
Kuban 2008 (32) 
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PROG 
95-09 
393 LR:58% 
IR: 37% 
HR: 5% 
70.2 GyE in 
39 fractions 
vs 79.2 GyE 
in 44 
fractions 
(proton 
boost) 
No 8.9 years HR 0.57 for 
local failure in 
dose-
escalation 
group 
10-year BFR 
32.0% vs 
17.4% 
(p=0.0001) 
10-year OS 
78.4% vs 
83.4% 
(p=0.41) 
Late grade ≥3 GU 
2% 
Late grade ≥3 
GI 1 % 
(both groups, 
p=NS) 
 
Zietman 2010 (36) 
Dutch 
trial 
(CKTO 
6910) 
664 IR: 27% 
HR: 55% 
68 Gy in 34 
fractions vs 
78 Gy in 39 
fractions 
Yes, 22% 
of pts 
9.2 years BCFR 46% vs 
52% 
(p=0.025) 
CFR 34% vs 
37% (p=0.4) 
PCD 13% vs 
13% (p=0.8) 
OS 31% vs 
30% (p=0.9) 
7-year late grade ≥2 
GU 40% vs 41% 
(p=0.6) 
Late grade ≥2 
GI 25 % vs 35% 
(p=0.04) 
 
Heemsbergen 2014 (35) 
Al-Mamgani 2008 (34) 
RTOG 
0126 
1532 70% had 
PSA < 10 
ng/ml, 84% 
with GS 7, 
57% had T1 
disease 
70.2 Gy in 39 
fractions vs 
79.2 Gy in 44 
fraction 
No 7 years 10-year OS 
66% vs 67% 
(p=0.87) 
BFR 43% vs 
26% 
(p<0.0001) 
LPR 8% vs 
4% 
(p=0.0059) 
DMR 8% vs 
5% (p=0.026) 
STR 21% vs 
13.5% 
(p=0.0002) 
Late grade ≥2 
GU/GI 37% vs 45% 
(p=0.0012) 
Time to late grade ≥ 
3 GI was higher for 
the 79.2Gy arm 
(p=0.035) but time 
to late grade ≥ 3 GU 
toxicity was not 
(p=0.14) 
Michalski 2015 (40) 
GETUG 
06 
306 HR: 29% 70 Gy in 35 
fractions vs 
80 Gy in 40 
fractions 
No 5 years BRR 39% vs 
28% 
(p=0.036) 
 
Late grade ≥2 GU 
10% vs 17.5% 
(p=0.046) 
Late grade ≥2 
GI 14 % vs 19.5% 
(p=0.22) 
 
Beckendorf 2011 (37) 
ADT=androgen deprivation therapy, MRC=Medical Research Council, IR=intermediate-risk, 
HR=high-risk, BPFS=biochemical progression-free survival, OS=overall survival, 
GU=genitourinary, GI=gastrointestinal, MDACC=MD Anderson Cancer Centre, 
FFBF=freedom from biochemical failure, FFDM=freedom from distant metastasis, NS=not 
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significant, GyE=Grey Equivalent, HR=Hazard ratio, BFR=biochemical failure rate, 
BCFR=biochemical failure rate, CFR=clinical failure rate, PCD=prostate cancer death, 
PSA=Prostate-specific antigen, GS=Gleason score, LPR=local progression rate, DMR=distant 
metastasis rate, STR= salvage therapy rate, BRR=biochemical relapse rate  
 
Meta-analysis of above referenced six dose-escalation trials that included more than 2800 
patients revealed that each 1-Gy increase in radiotherapy dose reduce the risk of biochemical 
failure by 1.8%, where the theoretical dose of 90 Gy would theoretically yield almost 100% 
rate of biochemical control (42).  
Similarly, Zaorsky et al. performed meta-analysis of 12 randomized controlled trials with 6884 
patients that evaluated dose escalation or hypofractionation, using calculated biologically 
equivalent doses (BED) for each schedule (alpha/beta=1.5). He found that BED escalation 
resulted in improved biochemical control at up to 10 years, but no improvement in overall 
survival, distant metastasis and cancer-specific mortality was observed (43).    
 
1.5. Interaction of radiotherapy dose escalation and androgen deprivation therapy   
 
Androgen deprivation therapy (ADT) is often given in conjuncture with radiotherapy as this 
approach improves outcomes for intermediate and high risk PCa. ADT and radiotherapy have 
the synergistic effect meaning that this combination mimics dose-escalation effect. This 
practically translates into notion that lower dose radiotherapy treatment combined with ADT 
produces the similar outcomes as the high dose radiotherapy alone. This observation is 
confirmed with the results from several  randomised trials of combination of ADT and 
radiotherapy which established level one evidence supporting this combination in high-risk 
prostate cancer (44–49). Having said, the optimal radiotherapy dose in the setting of combined 
modality treatment is still unknown. To illustrate this, in MRC RT01 trial which compared 64 
Gy with 74 Gy both in combination with 6 months of ADT, patients with high-risk PCa had 
better biochemical control  if treated on higher dose arm, although no effect on overall survival 
was observed (38). In EORTC 22991 study and the Quebec study both questions were 
addressed (radiotherapy dose and addition of ADT). EORTC 22991 study tested the effect of 
addition of 6 months of ADT to three different dose levels (70 Gy vs. 74 Gy vs. 78 Gy as per 
centre discretion), while Quebec study similarly tested 70 Gy vs 76 Gy ± 6 months of ADT 
(50,51). Results of these important studies were similar: biochemical control was indeed 
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improved in ADT arm compared to radiotherapy alone arm, regardless of radiotherapy dose 
received.   
Nowadays, it has become a contemporary standard in Europe to treat prostate with doses of at 
least 74 Gy (as per dose-escalated arm of MRC RT01 trial) when 2-Gy fractionation is used. 
However, in many US centres prescribed doses are even higher, ranging from 75.6 Gy 
(University of Michigan) to ultra-high doses of 86.4 Gy (Memorial Sloan Kettering Cancer 
Centre), both in 1.8-Gy fraction schedule. In Canada, most common standard EBRT 
fractionation is 78 Gy given in 39 fractions. Furthermore, overwhelming majority of high-risk 
patients and considerable portion of intermediate risk patients also receive additional ADT. 
However, late genitourinary and gastrointestinal side-effects limit our ability to safely escalate 
the dose as we have probably reached the limit of dose escalation in the range of >80 Gy. As 
current evidence points out, it is less likely to observe benefit of dose escalation beyond 74 Gy 
in the presence of ADT (50). Anyhow, contemporary series using doses above 74 Gy report 
long-term biochemical control rates in range 65%-90% depending on patient population.      
 
1.6. Addition of androgen deprivation therapy to improve radiotherapy outcomes 
 
Number of randomized studies investigated combination of androgen deprivation therapy and 
radiotherapy in PCa to improve patient clinical outcomes. Rationale for this combination came 
from seminal observation of Huggins and Hodges that prostate cancer cell heavily depend on 
the androgens (52).  Biological basis of added efficacy of combination of ADT and radiation 
although not yet fully understood, implies several important aspects: a) tumor can be controlled 
with diminished radiotherapy dose in the presence of ADT (53); b) neoadjuvant ADT increased 
overall tumor cell kill in animal models and caused retardation in residual tumor growth (54); 
c) ADT has suppressive impact on tumor vascularisation (55). By normalizing tumor 
vascularisation, androgen deprivation is decreasing hypoxia (56), the common feature in 
prostate cancer associated with radiation resistance, aggressive phenotype and development of 
metastasis (57). On clinical level, neoadjuvant androgen deprivation sensitizes tumor to 
radiation, thereby improving radiotherapy local control and reduces the second wave of 
metastasis (58).    
On systemic level, androgen deprivation therapy, by means of inhibition of DNA synthesis and 
cell proliferation, promoting apoptosis of cancer cells, may prevent the spread of 
micrometastatic disease (59).   
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Mainstay of combination of androgen deprivation therapy and radiotherapy is in the 
intermediate-, and high-risk disease. Using either neoadjuvant or adjuvant ADT, randomized 
phase III clinical trials have consistently shown that the combined-modality treatment with 
ADT and radiotherapy improves biochemical relapse-free, metastasis-free, and overall survival 
in high-risk and locally advanced disease compared with the use of either ADT or radiotherapy 
alone. Currently, the common standard is to give 6 months of androgen deprivation therapy in 
unfavourable-intermediate patients, and 2-3 years in high-risk disease. Even in the presence of 
EBRT dose escalation, ADT is necessary to optimize outcomes for unfavourable prostate 
cancer patients. In the study done by Zapatero et al., which included 355 patients with 
intermediate-risk and high-risk prostate cancer, who all received dose-escalated radiotherapy 
with a mean dose of 78 Gy, and were randomized to receive short-term (4 month duration) or 
long-term (28 month duration) ADT. With a median follow-up time of 63 months, patients 
treated with the long-term regimen demonstrated significantly higher 5-year biochemical 
progression-free survival (89.8% versus 81.3%, p = 0.019), higher rates of 5-year metastasis-
free survival (93.6% versus 83.4%, p = 0.009) and overall survival (94.8% versus 86.1%, p = 
0.01). The results of this trial underlay importance of ADT in patients receiving high-dose 
radiotherapy, which alone is not sufficient to prevent metastasis and increase the survival, as it 
fails to address the risk of primary occult or post-treatment secondary metastases. 
Overview of clinical trials addressing combination of androgen deprivation therapy and 
radiotherapy are presented in Table 4.   
 
 
 
Table 4. Overview of studies investigating combination EBRT and ADT to improve outcomes 
in localized prostate cancer.  
 
Trial Comparison Results 
RT±ADT   
RTOG 8610 
Pilepich et al. (60) 
65-70 Gy RT± 
2 months neoadjuvant ADT  
Improved local control 
Reduction in disease 
progression and disease-
specific mortality for patients 
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treated with neoadjuvant 
ADT 
 
EORTC 22863  
Bolla et al. (61) 
 
50 Gy RT to pelvis + 20 Gy RT to 
prostate and seminal vesicles ± 
adjuvant ADT for 3 years 
 
Improved 10-year OS in 
combined treatment (58.1% 
vs 39.8%, HR 0.60, p = 
0.0004)  
10-year PCSM 30.4% and 
10.3%, respectively (HR 
0.38, p <0.0001) 
 
DFCI 95096  
D’Amico et al. (62) 
 
70 Gy RT ± 6 months ADT  
 
13% OS benefit at 7.6 years 
with combined modality 
compared with RT alone 
RTOG 8531  
Lawton et al. (63) 
 
65–70 Gy RT ± adjuvant 
indefinitely ADT  
 
Improved absolute survival 
rate with adjuvant ADT 
compared with RT alone 
(49% versus 39%, p = 0.002) 
TROG 9601  
Denham et al. (64) 
 
66 Gy RT + 0, 3 or 6 months ADT 
 
Improved disease-free 
survival with 3 months ADT 
(HR = 0.65, p = 0.0001), and 
with 6 months ADT (HR = 
0.56, p <0.0001)  
 
RTOG 9408  
Jones et al. (49) 
 
66.6 Gy RT ± 4 months ADT  
 
Improved OS with combined 
modality treatment compared 
with RT alone (62% versus 
57%, HR 1.17, p = 0.03)  
 
EORTC 22991  
Bolla et al. (50) 
 
70/74/78 Gy RT ± 6 months ADT  
 
Improved 7-year 
biochemical and clinical 
disease-free survival with 
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ADT relative to without 
ADT  
ADT+RT 
 
  
MRC RT01  
Dearnaley et al. (65) 
 
6 months of ADT + 64 Gy or 74 Gy 
RT 
 
Improved 10-year 
biochemical progression-free 
survival in the dose-
escalation group (53%) 
compared with the standard-
dose group (43%) (HR 0.69, 
p=0.0003)   
   
EORTC 22961  
Bolla et al. (66)  
 
70 Gy RT + 6 months ADT vs  
70 Gy RT + 3 years ADT  
 
Inferior 5-year survival with 
6 months of ADT compared 
to 3 years of ADT (81% vs 
85%)  
 
RTOG 9202  
Horwitz et al. (48) 
 
65–70 Gy RT with 4 months of 
neoadjuvant and concurrent ADT ± 
additional 6 months ADT  
 
Improved disease-free and 
distant metastasis-free 
survival in the long-term 
ADT group.   
For men with GS 8–10, long-
term ADT had significantly 
better OS than short-term 
ADT.  
 
DART 01/05 GICOR 
Zapatero et al. (67) 
 
76 Gy RT with 4 months ADT or  
76 Gy RT with 24 months ADT 
All 5-year endpoints 
improved in longer ADT 
duration compared to shorter 
ADT duration (biochemical 
control 90% vs 81%; 
metastasis-free survival 94% 
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vs 83%; overall survival 95% 
vs 86%)    
 
RTOG 9910 
Pisansky et al. (68) 
2 months vs 7 months of 
neoadjuvant ADT followed by 70.2 
Gy to the prostate with 2 months of 
adjuvant ADT 
10-year incidence of 
locoregional progression 
(6% vs 4%, p=0.07), distant 
metastasis (6% vs 6%, 
p=0.8), and PSA recurrence 
(27% vs 27%, p=0.77)  
RT=radiotherapy, ADT=androgen deprivation therapy, RTOG=Radiation Therapy Oncology 
Group, EORTC=European Organisation for Research and Treatment of Cancer, HR=hazard 
ratio, PCSM=prostate cancer-specific mortality, DFCI=Dana Farber Cancer Institute, 
OS=overall survival, TROG= Trans Tasman Radiation Oncology Group, MRC=Medical 
Research Council, GICOR=Grupo de Investigación Clínica en Oncología Radioterápica.  
 
1.7. General radiobiology consideration  
 
Traditionally, EBRT is given in equal daily increments or fractions, five days a week to allow 
normal tissue to repair radiation injury and to allow tumours to re-oxygenate between the 
treatments. Re-oxygenation is known to be crucial for the efficacy of radiation-induced cancer 
cell kill as the hypoxic tumours are resistant to radiotherapy.  
Radiation prescription can be either standard (1.8 or 2 Gy fraction size), hypofractionated 
(fraction size>2 Gy and given in smaller number of daily fractions) or hyperfractionated 
(fraction size <2 Gy and given more than once daily). Daily fraction of 2 Gy is the standard in 
the radiotherapy as it is believed that this fraction size offer the best balance between desired 
tumour kill and unwanted normal tissue injury for most cancers.     
Generally, with increasing radiotherapy dose the number of surviving cancer cell is decreasing 
but instantly, the toxicity to surrounding tissues is also increasing. Linear-quadratic (LQ) model 
is widely used tool for quantitative prediction of dose and fractionation relationship in the 
radiotherapy (69). In LQ model, alpha/beta ratio is the measure of radiation fraction size 
sensitivity. More theoretically, alpha/beta ratio is the radiotherapy dose where linear and 
quadratic components of the cell kill are equal, as displayed on cell survival plot.   
The alpha/beta ratio is used in the calculation of the biologically equivalent dose (BED), which 
is the measure of true biological dose delivered by a particular combination of dose per fraction 
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and total dose to a particular tissue characterized by specific alpha/beta ratio. The following 
equation puts into relation BED and alpha/beta ratio: 
BED = nd * [1 + d / (a / b)] 
Where n is the number of radiation fraction, d is the fraction size and a/b is the alpha/beta ratio.  
Accumulating evidence over past 15 years points out that PCa is less likely to behave like other 
cancers as regards to its response to radiation. Most cancers, as well as all rapidly dividing 
normal tissues (like intestine or oral mucosa), have an alpha/beta of approximately 10 Gy. 
Those tissues are also called acute reacting tissues as they pronounce acute reaction to radiation 
injury (typical example is stomatitis, colitis or dermatitis which occurs during radiation). On 
other hand, slowly dividing late reacting normal tissues (i.e. fibroblasts, muscles, blood vessels, 
rectum, kidneys, lung, CNS) have an alpha/beta ratio between 3 and 5 Gy (70). Such late 
responding tissues exhibit radiation injury several months to years after irradiation.  
However, a number of studies and radiobiological models based on clinical data suggest that 
the alpha/beta ratio for prostate cancer is 0.9-1.5 Gy, which is surprisingly low (71–73). This 
implies that PCa cells are more sensitive to radiotherapy doses delivered in larger fraction size. 
Moreover, a low alpha/beta ratio for PCa means that hypofractionated radiotherapy would be 
more efficient in tumor kill than standard fractionated radiotherapy, and potentially will 
produce equivalent tumor control with lower total dose and shorter overall treatment time.  
Furthermore, alpha/beta ratio of 1.5 for PCa is lower than 3-5 Gy what is estimated alpha/beta 
ratio for rectum and bladder, surrounding late responding tissues and main organs-at-risk in 
PCa radiotherapy. This translates to the assumption that increasing the dose per fraction would 
increase BED for the PCa more than the BED for the rectum and bladder, thus increasing the 
therapeutic ratio (74).  
On the premises that low alpha/beta ratio render PCa more sensitive to larger fraction size and 
thus theoretically makes hypofractionated radiotherapy potentially more efficient compared to 
conventionally fractionated radiotherapy, several randomized trials comparing these two 
approaches were carried out. Trials were designed to test whether hypofractionated arm is 
either superior or “non-inferior” to conventional treatment arm. None of the studies so far 
(CHHiP, NRG RTOG 0415, Fox Chase Cancer Centre Study, Italian study, MD Anderson 
Cancer Centre study, Dutch HYPRO trial) found neither that hypofractionated treatment is 
superior to conventional dose-escalated treatment or has less late toxicities (65,75–77). As a 
result, it is still controversial what the optimal fractionation schedule for PCa is.  
Overview of studies comparing hypofractionated radiotherapy and conventional radiotherapy 
for localized PCa is presented in Table 5.   
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Table 5. Overview of studies testing the hypofractionation hypothesis in prostate cancer 
Trial RT schedule 
BED (Gy) 
Outcome Reference 
α/β=1.5 
(prostate 
cancer) 
α/β=3 
(normal 
tissue) 
α/β=10 
(tumor) 
Australian 
trial 
64 Gy/32fr 149 107 77 7.5-year BRFS 34% 
vs 53%  (p<0.05) 
7.5-year OS 69% vs 
71%  (p=NS) 
Yeoh 2011 
(78) 55 Gy/20fr 156 105 70 
Ontario 
(Canada) 
66 Gy/33fr 154 110 79 5-year BCF 52.95% 
vs 59.95% 
5-year OS 85% vs 
87% (p=NS) 
2-year PBR 53% vs 
51%  (p=NS) 
Lukka 2005 
(79) 52.5 Gy/20fr 145 98 66 
CHHiP 
(CRUK/06
/016) 
60 Gy/20fr 180 120 78 5-year FFBF 90.6% 
vs 85.9% (p=0.003) 
vs 88.3% 
Dearnaley 
2016 (65) 
57 Gy/19fr 171 114 74 
74 Gy/37fr 173 123 89 
NRG 
Oncology 
RTOG 
0415 
73.8 Gy/41fr 162 118 87 7-year DFS 75.6% 
vs 81.8% (p=NS) 
FFBF and OS not 
different 
Lee 2016 
(77) 70 Gy/28fr 187 128 88 
Fox Chase 
Cancer 
Center 
76 Gy/38fr 177 127 91 5-year BCDFR 
21.4% vs 23.3% 
(p=0.7) 
PCD and OS not 
different 
Pollack 
2013 (80) 70.2 Gy/26fr 197 133 89 
Italian 
80 Gy/40fr 187 133 96 5-year BFFS 79% vs 
85% (p=0.065) 5-
year FFLF 91% vs 
93% (p=0.33) 
5-year FFDF 86% vs 
90% (p=0.29) 
5-year CSS 82% vs 
92% (p=0.16) 
5-year OS 92% vs 
98% (p=0.13) 
Arcangeli 
2012 (81) 
 
62 Gy/20fr 190 126 81 
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MDACC 
72 Gy/30fr 
 
 
187 130 89 
5-year PSAFFS 96% 
(p=NS) 
Kuban 2008 
(32) 
 
75.6 Gy/42fr 166 121 89 
5-year PSAFFS 92% 
(p=NS) 
 
Table legend: BED=biological equivalent dose, BRFS=biochemical relapse-free survival, 
OS=overall survival, BCF=biochemical/clinical failure, PBR-positive biopsy rate, 
CRUK=Cancer Research UK, FFBF=freedom from biochemical failure, GU=genitourinary, 
GI=gastrointestinal, DFS=disease-free survival, PCD=prostate cancer death, OS=overall 
survival, NS=not significant, BCDFR= biochemical and/or clinical disease failure, 
BFFS=biochemical failure-free survival, FFLF=freedom from local failure, FFDF=freedom 
from distant failure, CSS=cancer-specific survival, MDACC=MD Anderson Cancer Center, 
PSAFFS=PSA Failure-free survival.   
 
 
1.8. Biological effects of radiation and radiobiology of brachytherapy  
 
Main mechanisms how radiation kills cancer cells are atom ionization and creation of free 
radicals which induce chemical damages in target cell structures, primarily in the DNA. Effect 
on DNA (single-strand or double-strand break) provides the basis of biological effects 
associated with radiation. Cells are trying to repair DNA breaks using special repair enzymes 
machinery. If this machinery fails to repair DNA breaks, the cell is destined to dye, usually 
through apoptosis or programmed cellular death.   
Biological effects of radiotherapy are strongly dependent on the rate of dose delivery. In HDR 
brachytherapy, where the dose-rate is high, repair (repair of sublethal DNA damage between 
the radiotherapy fractions), repopulation (the increase in cell division – clonogenic cell survival 
after the radiation is delivered), and reoxygenation (increase in oxygenized and radiosensitive 
cell fraction of the tumor after the radiation is delivered) are the main biological factors 
determining treatment outcome. In HDR brachytherapy, repair, repopulation, and 
reoxygenation are less likely to happen as a consequence of short treatment time (i.e. big blast 
of radiation given only in few minutes) (82).          
The biological effects of radiotherapy build upon several important factors which primarily 
include delivered dose, dose distribution, treated volume, dose rate, fractionation and treatment 
  
18 
 
duration (82). In brachytherapy, treated volumes are usually small compared to EBRT volumes, 
and characteristically, the dose distribution is very heterogeneous. In brachytherapy, as 
opposed to EBRT, treatment is delivered continuously (i.e. within several minutes in HDR 
brachytherapy) without gaps, allowing no repair, which can occur in EBRT during treatment 
gaps.    
Based on different dose rates, brachytherapy can be divided into several categories, as 
described in ICRU report 38 (83). Low Dose Rate (LDR) brachytherapy covers spectrum 
between 0.4 and 2 Gy/h, and this kind of radiation is delivered using conventional manual or 
automatic afterloading techniques. Permanent radioactive implants with very low dose rate (i.e. 
125-I permanent seed prostate brachytherapy) which deliver very high dose (145 Gy) over the 
course of several months fall under this category.   
Medium Dose Rate (MDR) brachytherapy is positioned between 2 Gy/h and 12 Gy/h, while 
high dose rate (HDR) brachytherapy has dose rate of ≥12 Gy/h employing high activity sources, 
requiring delivery by using automatic afterloading systems only.  
 
 
1.9. Brachytherapy treatment options (LDR and HDR)  
 
Brachytherapy is old radiotherapy technique where the radioactive source is introduced into 
vicinity of the tumor or into the tumor itself and has tradition over 100 years (84). In case of 
PCa, radiation is targeted directly at the prostate through radiation source that is either 
implanted (permanent seed brachytherapy or low-dose-rate-LDR) or temporarily placed within 
the prostate (high-dose-rate brachytherapy or HDR). Brachytherapy actually has preceded 
EBRT as latter was developed much later due to considerable technology requirements. 
Brachytherapy is known to be the most conformal radiotherapy technique for PCa because of 
rapid dose fall off outside of the prostate, by the virtue of inverse-square law. In the work done 
by Dr. Georg, HDR and LDR brachytherapy were dosimetrically compared with the most 
advanced radiotherapy techniques: volumetric modulated arc therapy (VMAT), intensity 
modulated proton therapy (IMPT) and scanned carbon-ion therapy (as most advanced 
modalities of particle therapies), in a terms of radiation doses to rectum and bladder wall. The 
lowest doses to the rectum and bladder wall were associated with HDR brachytherapy in this 
planning study (85).     
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Brachytherapy allows safe dose escalation (>140 Gy) as the dose to the rectum and bladder are 
kept minimal. Furthermore, there are no uncertainties related to prostate movement, as the 
implanted sources move with the prostate. Even the most contemporary EBRT techniques such 
as IMRT or volumetric arc therapy (VMAT) fail to match superb conformality associated with 
HDR brachytherapy as significant volume of the rectum still receive substantial dose in EBRT 
plans (Figure 1). As a result of tight dose conformity, in HDR brachytherapy less radiation is 
received by rectum and bladder, thus reducing the incidence of urinary, sexual and bowel side-
effects compared to surgery or EBRT (86) and minimizing the risk of secondary malignancies 
(87). In terms of health economics, brachytherapy is favourable as treatment delivery time is 
shorter compared to EBRT and set-up and maintenance cost are considerably lower compared 
to contemporary EBRT delivery (88).   
 
 
 
 
Fig. 1. Isodose distribution of high-dose-rate (HDR) (b) and external beam radiotherapy 
(EBRT) delivered using volumetric modulated arc therapy (VMAT) (c). HDR implant delivers 
much higher dose within the prostate with fewer doses to surrounding tissue. Even when the 
most contemporary EBRT technique (VMAT) is being used, significant high dose volumes 
cover surrounding tissues (so called wash-out dose). Please note 50% isodose encompassing 
almost all rectum. Reproduced from ref. (89), courtesy by Dr. Morton.   
Both LDR and HDR represent appealing brachytherapy options with proven track record 
accumulated over 15 years of clinical experience. We now have two randomised trials (UK 
trial and Canadian British Columbia Cancer Agency trial) showing improved biochemical 
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relapse-free survival for patients receiving combination of brachytherapy and EBRT compared 
to EBRT alone (90,91). In UK trial led by Hoskin, EBRT was hypofractionated (55 Gy in 20 
fractions in EBRT alone arm and 35.75 Gy in 13 fractions in the brachytherapy boost arm), 
and boost was given as HDR implant of 2 fractions of 8.5 Gy. Five, seven, and 10-years 
recurrence-free survival for the boost arm was 75%, 66%, and 46%, respectively as opposed to 
61%, 48%, and 39%, respectively in EBRT alone arm. In BCCA trial EBRT dose was 78 Gy 
in EBRT alone arm and 46 Gy in the brachytherapy boost arm. Boost was given as 125-I LDR 
implant with 115 Gy of minimal peripheral dose. Five, seven, and nine-year biochemical 
progression-free survival for the LDR boost arm vs EBRT alone arm was 89% vs 84%, 86% 
vs 75%, and 83% vs 62%, respectively. It is possible that with extended follow-up an 
improvement in PCa-related mortality will emerge. Both of these trials set the benchmark for 
future studies and provide level one evidence supporting the use of brachytherapy boost for 
optimizing cure rates for localized prostate cancer.  
There is uniform consensus nowadays that treatment with brachytherapy, alone or combined 
with EBRT, results in improved disease control compared to EBRT alone.   
When LDR and HDR are compared, several key points need to be made. The disadvantages of 
LDR brachytherapy are following: possible seed migration, permanent nature of deposition of 
radioactive sources in the prostate, and protracted overall treatment time (it takes 
approximately two months to deliver full dose using 125-I seeds due to slow radioactive decay). 
As per basic radiobiology concept, radiation treatment is more effective if it is delivered in 
shorter treatment time thus avoiding repopulation of tumor cells and recovery from sublethal 
damage (70). HDR on contrary has the edge here. Using advanced technology now available 
in the routine practice, it is possible to automatically deploy and retract HDR brachytherapy 
source (192-Ir) along the specified catheter path. Remote after-loading system controls the 
source which travels along the catheter(s) and dwells in specified positions in order to deliver 
prescribed radiotherapy dose. Inverse dose optimisation planning is used to produce 
radiotherapy plan which in terms of conformality and prostate coverage regularly supersede 
EBRT or LDR dose distribution. Furthermore, the possibility of the seed migration is minimal 
as the source is located in the plastic hollow catheter that is inserted into prostate. In HDR dose 
optimization is done after catheter placement, therefore it allows more consistent target 
coverage with live dose sculpting compared to permanent seed implants. This finally leads to 
improved dose conformity, and lower doses to urethra and rectum typical for HDR 
brachytherapy (92).   
  
21 
 
Furthermore, related to HDR, there is no radiation exposure for staff and one HDR source can 
serve multiple patients requiring HDR brachytherapy either intracavitary or interstitial 
(gynaecological, prostate, head and neck, lung, etc.) leading to improved cost-effectiveness. 
Using HDR it is also possible to cover microscopical disease outside of prostate in case of 
high-risk disease while low-energy LDR cannot cover areas distant to prostate capsule, which 
is inherent limitation of low-energy beta decay of 125-I.  
On other hand, HDR brachytherapy is not devoid of limitations. Potential for catheter 
displacement and consequential impaired dosimetry is significant, especially if the patient is 
being transferred from implantation phase to planning phase (in case of CT planning) and 
between planning and treatment delivery (93). If the patients are moved, consequential 
displacement of catheters can easily occur. Displacement within few millimetres would lead to 
deterioration in dosimetry emphasizing critical importance of catheter position verification. 
Finally, HDR dosimetry is not depended on prostate volume changes that occur over the course 
of time compared to LDR dosimetry where swelling of the prostate after implantation 
significantly affects quality of the implant (94).                   
HDR brachytherapy is well established treatment option in PCa, however the mainstay of HDR 
today is boost to EBRT where the 5-years biochemical control rates for men with low-risk, 
intermediate-risk, and high-risk PCa are in range >85%, 69-97%, and 63-80%, respectively 
(95–97). As a result of the benefits of delivering highly conformal dose-escalated radiation, 
HDR brachytherapy has been recognized and routinely recommended, either alone or in 
combination with EBRT, for the treatment of PCa by major professional bodies (American 
Brachytherapy Society (ABS), Groupe Européen de Curithérapie (GEC), and Europen Society 
for Radiotherapy and Oncology (ESTRO) (98,99).  
   
1.10. Rationale for combining HDR brachytherapy and EBRT  
 
There are several reasons behind the use of HDR brachytherapy in combination with EBRT. 
Firstly, external beam dose escalation above 70-76 Gy is necessary to optimize probability of 
cancer control. Secondly, HDR allows unparalleled target dose conformity and sparing of 
adjacent organs-at-risk. Thirdly, postulated low α/β ratio for prostate cancer provide 
radiobiological basis for delivering larger doses per fraction (by means of HDR or 
hypofractionation). Fourthly, abundance of mature clinical data support the use of this 
combination (100).     
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As we previously discussed, further dose escalation by EBRT is limited by increased rectal 
toxicity, despite advances in modern EBRT techniques (101). On other side, hypofractionated 
EBRT has been investigated as the alternative method of radiotherapy dose escalation by 
increasing BED. However, results of clinical trials so far are not conclusive and this issue is 
matter of current debate, underlying uncertainty of this approach (80).    
 
As previously said, HDR brachytherapy is usually combined with either conventionally 
fractionated or hypofractionated course of EBRT. In the case of hypofractionated EBRT, 
advantages of both radiotherapy components are being exploited. As a backbone, EBRT 
provide basic dose escalation. It allows intraprostatic dose escalation (increasing BED) and 
escalation of the dose in the vicinity of the prostate to cover eventual extracapsular extension 
and seminal vesicle invasion, which are not within the therapeutic range of HDR 
brachytherapy. Furthermore, it allows entire pelvis and pelvic lymph nodes to be treated (i.e. 
for high-risk patients). Lastly, in the case of eventual substandard HDR implant with poor 
dosimetry, supplemental EBRT can compensate for that.    
Body of evidence supporting the use of HDR brachytherapy boost is impressive, and include 
numerous single-centre studies with total of 5000 patients treated with median follow-up of up 
to 10 years (100). However, there is wide variation in dose and fractionation used. Average 
biochemical disease-free survival in these studies is steadily high: 95%, 91%, and 82%, for 
low-, intermediate-, and high risk patients, respectively. HDR treatment is generally well 
tolerated, with rare late Grade 3 rectal toxicity. Most common side-effects are genitourinary 
(dominantly late strictures); with late Grade 3 toxicity rates being between 1% and 14%. 
Overview of clinical results (biochemical recurrence-free survival and toxicity) of 
contemporary series of patients treated with HDR boost supplemental to EBRT is presented in 
Table 6.  
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Table 6. Overview of results of major modern series of HDR brachytherapy boost combined 
with EBRT with biochemical disease-free survival by risk grouping and late Grade 3 urinary 
(GU) and gastrointestinal (GI) toxicity. Modified from ref. (100), courtesy by dr. Morton.    
 
Author (ref) N 
Median 
follow-
up 
(months) 
Late 
grade 3 
toxicity 
(%) 
bDFS by risk group 
(%) 
Dose/fraction 
(EBRT+HDR) (Gy) 
G
U 
GI Lo
w 
Intermedia
te 
Hig
h 
Agoston 
(102) 
100 62 14 2  84 82 60/30+10/1 
Aluwini 
(103) 
264 75 4 1 97   45/25+18/3 
Bachand 
(104) 
153 44    96  44/22+18/2-20/2 
Cury (105) 121 63 2 2  91  50/20+10/1 
Deutsch 
(106) 
160 53   100 98 93 50.4/28+21/3 
Galalae 
(107) 
122 117 5 3 88 71 72 50/25+18-30* Gy/2 
Ghadjar 
(108) 
64 61 14 0  100 91 50/25+21/3 
Kaprelian 
(109) 
64 
101 
105 
43 
1 
 
0  
84 
94 
80 
82 
45/25+18/3 
45/25+19/2 
Khor (110) 344 61 2 0  84 74 46/23+19.5/3 
Kotecha 
(111) 
229 61 5 0.4 95 90 57 50.4/28+16.5-22.5/3 
Lilleby 
(112) 
275 44    100 
98.
8 
50/25+20/2 
Marina 
(113) 
282 96    91  46/23+19-23/2 
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Martinez-
Monge 
(114) 
200 44 5 2   85 54/27+19/4 
Morton 
(115) 
60 
123 
72 
45 
4 
1 
0 
0 
 
98 
95 
 
45/25+20/2 
37.5/15+15/1 
Neviani 
(116) 
455 48 8 1 92 88 85 45/25+16.5/3-21/3 
Pellizon 
(117) 
209 64   92 90 89 45/25+20/2 
Phan (118) 309 59 4 0.3 98 90 78 
36/18-50.4/28+15/3-
26/4 
Pistis (119) 114 32     97 60/30+10/1 
Prada (120) 313 68 2 0 100 88 
79-
91 
46/23+23/2 
Savdie (121) 90 95     80 45/25+16.5/3 
Whalley 
(122) 
101 56 2 0  95 66 46/23+19.5/3-17/2 
Zwahlen 
(123) 
196 66 7 0  83  46/23+20/4-18/3 
* 30 Gy to peripheral zone, 18 Gy to anterior prostate. 
To supplement discussed clinical results, several clinical scenarios of radiotherapy treatment 
options for PCa are presented in Table 7. Please note the combination of course of EBRT and 
single fraction HDR boost yield the highest BED (biologically equivalent dose) while EBRT 
alone has the lowest BED. Owing to low α/β (1.5 Gy) for prostate cancer these BEDs are much 
higher than BEDs for organs-at-risk (α/β=3) illustrating improved therapeutic ratio for 
combination therapy (EBRT+HDR).    
High BED associated with combination of HDR brachytherapy and hypofractionated EBRT is 
key reason of excellent clinical results of this increasingly popular combination.   
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Table 7. Examples of BED (biologically equivalent dose) calculations for several clinical 
scenarios with different radiotherapy modalities and schedules with α/β of 1.5 (prostate cancer) 
and 3 (rectum).   
   
Dose (Gy)/fractionation 
EBRT+HDR vs HDR mono vs EBRT mono   
BED/Gy 
(α/β=1.5) 
BED/Gy 
(α/β=3) 
46/23# (EBRT) + 15/1# (HDR) 272 167 
45/25# (EBRT) + 15/1# (HDR) 264 162 
37.5/15# (EBRT) + 20/2# (HDR)  253 156 
37.5/15# (EBRT) +15/1# (HDR) 265 158 
19/1# (HDR monotherapy)  260 139 
15/1# (HDR monotherapy)  165 90 
84.6/47# (EBRT monotherapy)  186 135 
78/39# (EBRT monotherapy)  182 130 
#=fractions 
  
 
1.11. Image guidance modalities for HDR brachytherapy  
 
Transrectal ultrasound (TRUS) has been the standard imaging guidance modality for HDR 
brachytherapy. Since introduction of TRUS in the 1980s by Holm to guide implantation of 
radioactive seeds into prostate and enable planning (124), TRUS has become increasingly 
popular and probably most widely accepted intraoperative image guidance tool (Fig. 2). TRUS 
undoubtedly has some relative advantages compared with CT and MRI as eventual competing 
image guidance tools. TRUS enables fair visualization of the prostate and urethra facilitating 
accurate standard arrangement implantation (125,126). Probably the biggest TRUS asset is 
possibility to guide needle insertion in the real-time. Intraoperative TRUS-based prostate HDR 
brachytherapy allows for prostate implantation, imaging, planning, and treatment to be 
performed in a single session with the patient in the same position throughout the procedure. 
This minimizes the possibility of catheter migration and subsequent inaccurate treatment 
delivery, a serious cause of concern in every brachytherapy method (127). However, TRUS-
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based HDR brachytherapy is not without difficulties and limitations. Ultrasound images are 
limited in their ability to objectively delineate needles paths; cannot differentiate tumor lesion 
within the prostate or unequivocally detect extraprostatic disease extension, and are susceptible 
to acoustic shadows (128). For this reason, catheters are often implanted at the prostate 
boundary to aid segmentation of the prostate in a degraded final TRUS image.     
 
 
 
Fig. 2. Schematic illustration of transperineal insertion of brachytherapy needles using 
transrectal ultrasound (TRUS) guidance.   
 
 
In TRUS-based procedure, live TRUS images are acquired with inserted catheters and 
transferred to the planning system. Prostate, urethra, bladder, and rectum are contoured, 
catheters identified and the treatment plan developed based on anatomy-based inverse 
planning. This form of planning optimize the dwell time at each position along the catheters to 
sculpt the dose to achieve target coverage while limiting dose to organ-at-risk (urethra, rectum) 
(89). The main advantage of TRUS-based planning is that the entire HDR brachytherapy 
procedure of catheter insertion, planning and treatment delivery can be carried out in a shielded 
brachytherapy suite without movement of patient. TRUS-based HDR brachytherapy is out-
patient 1.5-2 hour’s procedure during which the patient is under the general anaesthesia. 
Furthermore, TRUS-based planning is practical, convenient, and inexpensive.   
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Other potential image guidance modalities include computerized tomography (CT) and 
magnetic resonance imaging (MRI). Each of these modalities has their own advantages and 
limitations (Table 8).  
 
Table 8. Relative advantages and disadvantages for each imaging guidance modality for 
prostate HDR brachytherapy  
 
 CT MRI TRUS 
Catheter identification ++ ++ - 
Catheter tip localization ++ - - 
Prostate delineation - ++ + 
Critical structure delineation - ++ + 
Patient comfort  - -- ++ 
Cost, efficiency and convenience  - -- ++ 
CT=computerised tomography, MRI=magnetic resonance imaging, TRUS=trans-rectal 
ultrasound  
 
CT has the advantage of being geometrically accurate and is so far the gold-standard imaging 
modality for identifying the needle/catheters locations and its tip (129). However, it has poor 
capacity for prostate delineation and often requires the patient to be moved from the procedure 
room to the imaging suite and then back to the treatment vault. These multiple transfers can 
result in displacement of needles and significant changes in implant geometry (93,130,131). 
Moreover, CT is resource- intensive requiring an available CT scanner and logistic support 
which increase cost of the procedure.  
 
 
1.12. Role of MRI in the prostate cancer management and HDR brachytherapy 
image guidance 
  
Magnetic resonance imaging (MRI) is being increasingly used in genitourinary imaging 
because of its superior soft tissue contrast compared to CT and TRUS. MRI offers 
unprecedented high quality image resolution and is increasingly used in the management of 
PCa. MRI is the most accurate imaging to assess local extent of PCa, depict zonal prostate 
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anatomy and to detect seminal vesicle invasion and/or extracapsular extension (132–134). 
Recently updated guidelines provided frame for reporting multiparametric MRI (mpMRI) 
findings through standardization of imaging protocols and brought more agreement in this 
evolving area (135–138).  
 
Briefly, prostate cancer has specific features on mpMRI supplemented by endorectal coil for 
optimal signal strength and image resolution and quality. On T2-weighted sequences, most PCa 
can be visualized as hypointense (darker) areas within the high-signal-intensity (gray) normal 
peripheral zone which is primary site of cancer in 70% of all PCa. On diffusion weighted 
imaging, PCa displays restricted (lower) diffusion compared with benign prostate tissue, with 
lower signal intensity on the ADC (apparent diffusion coefficient) map and hyperintense signal 
on high b-values compared to surrounding prostate tissue. On dynamic contrast-enchanced 
imaging, PCa typically shows early enhancement associated with abnormal tumor angiogenesis 
(139).  
MRI has been used both for EBRT and low-dose-rate brachytherapy treatment planning with 
the potential to allow better sparing of organs-at-risk, including erectile tissues (140,141). 
Moreover, MRI-delineated prostate target volumes proved to be up to 30% smaller than CT-
delineated volumes, resulting in higher treatment accuracy and avoidance of unnecessary 
radiation exposure of surrounding organs. In several studies that included patients treated either 
with EBRT or with combined EBRT and brachytherapy, MRI features proved to be predictive 
for biochemical relapse outcomes (142,143). There is also a notion to use MRI as a tool for 
adaptive external beam radiotherapy with the goal to develop and clinically employ MR-Linac 
as the next generation of image-guided radiotherapy (144).   
Multiparametric MRI has the added benefit as it combines anatomical information provided by 
T2-weighted MR images with functional imaging sequences, such as diffusion-weighted 
imaging (DWI), dynamic contrast-enhanced imaging (DCE), and magnetic resonance 
spectroscopic imaging (MRSI). These sequences combined provide extensive information on 
status of active disease within the prostate and beyond the gland (145,146).      
As previously elaborated, in HDR brachytherapy, where image guidance is an indispensable 
for accurate catheter placement, MRI additionally offers excellent soft tissue resolution, ideal 
brachytherapy catheter visualization, and better image quality compared to (TRUS). This asset 
of MRI may lead to better brachytherapy plan optimization, target coverage, intraprostatic 
tumor dose escalation, and sparing of organs-at-risk (rectum and urethra) that could potentially 
turn in the long run in better long-term cancer control and less treatment-related side-effects. 
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Moreover, it allows HDR treatment planning and delivery to be based on 3D MRI images, and 
allows precise identification of brachytherapy catheters relative to the target volumes and 
adjacent normal tissues.  
However, the main limitations of MRI in the context of HDR brachytherapy remain the high 
cost and scarce availability as it presents many logistical and resource issues.   
 
Comparison of prostate imaging modalities, TRUS, CT and MRI is presented in Fig. 3. Please 
note superior soft tissue contrast in MR image, resulting in clear visibility of the prostate, 
intraprostatic tumor lesion and surrounding anatomy as compared to TRUS and CT.  
 
 
Fig. 3. Comparison of the TRUS, CT, and MRI in prostate imaging. On the far right panel, 
depicting MRI, asterisk indicates cancerous lesion in the prostate and arrowhead indicates 
clearly distinguishable and defined prostate capsule (from ref. (147)).   
  
 
1.13. Rationale for proposed research  
 
First experience with MRI-guided brachytherapy was gained by Dr. Cynthia Ménard at 
National Institutes of Health (Bethesda, MD) in early 2000s using standard, 1.5T “closed-bore” 
scanner (Fig. 4). This was pilot study on 5 patients which were treated with EBRT and received 
HDR boost before and after the course of EBRT. T2-weighted MRI images were used and 
achieved dosimetry was very favorable. This early study showed that HDR brachytherapy in a 
standard 1.5T MRI scanner is feasible (148).  
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Fig. 4. Magnetic resonance imaging (MRI) scanner room setup with patient in decubitus 
position during the first MRI-guided HDR brachytherapy for prostate cancer, reproduced from 
ref. (148), courtesy of dr. Ménard.     
 
Later on, the interests of group led by Dr. Ménard switched to MRI-guided, tumor targeted 
HDR brachytherapy as salvage treatment for locally recurrent prostate cancer. In this program, 
multi-parametric MRI integrated with guided biopsies proved to be crucial tool to achieve 
geometric precision and effective salvage treatment (149).  
In this study a modified transperineal stereotactic template-based biopsy technique was used 
in the online MR imaging environment with endorectal coil in place (150).  
Based on this encouraging experience, Dr. Ménard as principal investigator (PI) in MRI-guided 
HDR brachytherapy program at Princess Margaret Cancer Centre, decided to prospectively 
include patients planned for standard-care HDR brachytherapy whole gland boost to EBRT on 
MRI-guided program. Furthermore, the eventual benefit of MRI guidance has never been 
clinically proven in this setting.   
 
Phase II prospective trial was designed with objective to assess feasibility, safety, and value of 
a technique using interventional MRI for online guidance of catheter insertion and treatment 
planning in patients receiving HDR brachytherapy boost for intermediate- and high-risk 
localized prostate cancer. The novelty of this concept lays in the exclusive use of MRI both for 
brachytherapy catheter image guidance and treatment planning. This study builds on early work 
on this method using MRI scanner prototype and procedure workflow developed by Dr. 
Ménard, as previously described (150). Furthermore, this work continues on our pilot study 
which enrolled patients receiving HDR whole gland boost where we observed this unique 
technique based on interventional MRI provide additional data that allow more accurate target 
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coverage, organ-at-risk sparring and plan optimization (151). Encouraged by these initial 
results, in this study we enrolled total of 40 patients in Princess Margaret Cancer Centre in 
Toronto that were treated together by study P.I. (Dr. Ménard) and PhD candidate (Dr. Murgic). 
This study has been IRB approved (University Health Network Research Ethics Board No 09-
0026-C). Aim of this study was to assess feasibility, safety and value of MRI image guidance 
in the context of whole gland HDR boost.   
 
 
2. HYPOTHESIS  
 
Interventional MRI-guidance as novel technique for high-dose-rate (HDR) brachytherapy for 
prostate cancer is feasible and safe.  
 
 
3. AIMS AND PURPOSE OF THE RESEARCH   
 
3.1. GENERAL AIM: 
To assess feasibility, safety, and value of a technique which utilize interventional MRI for 
online guidance of catheter insertion and treatment planning in patients receiving HDR 
brachytherapy boost for intermediate- and high-risk localized prostate cancer.  
 
3.2. SPECIFIC AIMS: 
 
To determine:  
1. the frequency, nature, and clinical impact of gross tumor visualization through the 
course of the HDR brachytherapy procedure-related workflow efficiencies (primarily 
refers to procedure time) 
 
      2.  dose metrics of implant quality:   
            a) PTV V100 (planning target volume receiving 100% of prescribed dose) 
            b) PTV D90 (dose received by the 90% of planning target volume) 
            c) urethra V105 (volume of urethra receiving 105% of the prescribed dose) 
            d) rectum V75 (volume of the rectum receiving 75% of the prescribed dose)  
            e) bladder V75 (volume of the bladder receiving 75% of the prescribed dose))   
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4. acute and late toxicity and health related quality of life   
 
5. patient's clinical oncologic outcomes  
            (biochemical disease-free survival, metastasis-free survival)  
 
 
4. MATERIALS AND METHODOLOGY   
 
The research was done at the Radiation Medicine Program in Princess Margaret Cancer Centre 
of the University Health Network and University of Toronto Department of Radiation 
Oncology, Toronto, Canada, under mentorship of professor Cynthia Ménard, MD, FRCPC as 
part of the project “MRI-Guided HDR Brachytherapy for Prostate Cancer” (REB#09-0026-C). 
Study was funded by Ontario Consortium for Adaptive Interventions in Radiation Oncology, 
Ontario Research Fund (project number RE-04-026) matched to an industry grant provided by 
Hologic Inc. 
 
4.1. Patient population  
 
Total of forty (40) patients were enrolled on prospective, single cohort, non-randomized, open-
labeled, interventional, IRB-approved, single-center trial (NCT registration number 00913939) 
recruiting patients to receive whole gland prostate HDR brachytherapy boost under MRI 
guidance, combined with supplemental EBRT. This trial was based in Princess Margaret 
Cancer Centre, University Health Network Department of Radiation Oncology University of 
Toronto, Canada, where all the patients were treated. This study enrolled patients with prostate 
cancer who were receiving HDR brachytherapy boost in conjunction to EBRT. Study 
intervention consisted in the use of MRI for image guidance for brachytherapy procedure, and 
this is basic concept of this protocol. PI of the trial was Dr. Cynthia Ménard, the pioneer in use 
of MRI imaging in HDR brachytherapy for prostate cancer and the PhD candidate Dr. Jure 
Murgic, who worked closely with Dr. Ménard as brachytherapy fellow in Princess Margaret 
Cancer Centre, analyzed patient and treatment-related data acquired throughout this trial.  
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4.2. Inclusion and exclusion criteria for the study  
 
Eligible patients for this trial were those with intermediate- or high-risk prostate cancer 
according to NCCN criteria (stage T2/3 or PSA>10 or Gleason score>6), with no evidence of 
nodal or distant metastasis. Trial intervention is basically associated only with regards to MRI 
guidance for HDR brachytherapy boost. Other elements of patient care, such as doze of HDR 
boost, fractionation of EBRT, use of hormonal therapy, etc. were delivered as per standard of 
care. Hormone therapy was allowed and prescribed at the discretion of treating oncologist. 
Exclusion criteria for trial were: contraindications to MRI (patients weighing more than 136 
kg, or having pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic 
devices not compatible with MRI), bleeding diathesis, contraindications to endorectal coil or 
to anesthesia, International Prostate Symptom Score (IPSS)>18, large post-transurethral 
resection of the prostate (TURP) defect, TURP within the past 6 months, prostate gland volume 
>80 cubic centimeters, and history of bowel inflammatory disease. Patients had to be staged 
clinically, primarily using digital rectal examination and TRUS. Bone scan and CT scan of 
abdomen and pelvis were performed in high-risk patients to exclude the presence of distant 
metastasis.  
 
 
 
4.3. Interventional MRI procedure and MR imaging details  
 
Patients were immobilized in a frog-leg position on an interventional MRI tabletop (Sentinel 
Endocoil Array System by Invivo), Figure 5.  
 
 
 
 
 
 
 
 
 
  
34 
 
 
 
Figure 5. 3T-MRI scanner, interventional MRI tabletop with movable MRI table which can be 
undocked for patient transportation purposes.    
 
The procedure was performed under intravenous anesthesia with propofol (Diprivan, Astra 
Zeneca, London, UK) and laryngeal mask airway. A Foley catheter was inserted in the bladder 
for the duration of the procedure, and the Foley balloon inflated with diluted X-ray contrast. A 
sterile MRI-compatible perineal template was affixed perpendicular to the endorectal coil and 
positioned and immobilized against the perineum (Fig. 6). Whole team working in the 
procedure is depicted on Fig. 7.  
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Figure 6. MRI setup system consisting of body coil, four-channel phased-array pelvic surface 
coil, and endorectal coil which is affixed with the perineal template.  
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Fig. 7. Team required for smooth running of the procedure (radiation oncologist with 
brachytherapy expertise, brachytherapy technician, MRI technician, anesthetist, and anesthetist 
technician). Note the patient position – frog leg, with legs first to the scanner. MRI table is 
undockable and transferable.  All equipment is MRI safe.   
 
  
 
Fig. 8. MRI scout images for the purpose of endorectal coil and perineal template registration 
allowing stereotactic navigation of the needles. Each hole in the template has unique 
coordinates, allowing needle tracking.    
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MR images were acquired for device registration (Fig. 8) (steady-state free precession imaging 
of the template system) and depiction of anatomic details facilitated with body coil used for 
excitation and a four-channel phased-array surface coil placed anterior to the pelvis combined 
with the endorectal coil for signal reception. Procedures were initially performed using a 1.5 T 
MRI scanner (Signa; GE Medical Systems, Milwaukee, WI) but subsequently migrated to 
using a 3T MRI scanner (IMRIS, Minnetonka, MN), Figure 5. T2-weighted Turbo Spin Echo 
(TSE) axial images (Field-of-view (FOV) 140 mm, TR (Repetition Time) 2500 ms, TE (Echo 
Time) 100 ms, matrix 320 x 320, voxel resolution 0.4 x 0.4 x 2.0 mm) and diffusion-weighted 
imaging-DWI (FOV 180 mm, TR 6000 ms, TE 83 ms, matrix 128 x 128, voxel resolution 1.4 
x 1.4 x 3.0 mm, b (value) = 0; 100; 600; 1000) were acquired immediately before catheter 
insertion.  
Dynamic contrast-enhanced MRI (DCE-MRI) was not used as only PIRADS 4-5 lesions were 
considered (137,138). PIRADS 4 and 5 lesions represent high and very high probability of 
clinically significant prostate cancer being present in the prostate, based on the combinational 
analysis of the findings from T2w, DWI, and DCE-MRI sequences (152).  
Catheter placement was guided using template-based stereotactic navigation software (Aegis, 
Hologic, MA) which was supported by passive fiducial registration.  
This process was aided by MRI technician using displayed MR images in the procedure room, 
allowing the operator real-time feedback of the catheter position (Fig. 9).    
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Fig. 9. Catheter navigation using navigation software with in-room control of MRI using 
remote commands.    
 
 
The prostate was implanted via a peripheral loading technique with additional effort to insert 
catheters directly into any visualized tumor and within the prostate boundary.  
Technically, catheters were placed by withdrawing the scanner table, inserting a coaxial MR-
compatible needle (In Vivo, Germany), aided by stereotactic navigation software, to the depth 
at the level of prostate base. Afterwards, the MRI table was advanced back to the isocentre and 
fast-spin-echo images were acquired to verify needle positions. Upon achieving satisfactory 
needle position with the tip at the prostate base, a brachytherapy catheter (ProGuide, Nucletron) 
was inserted through the coaxial needle which was then removed. Several needles were inserted 
between each image verification sequence.  
 
Once catheters (ProGuide, Elekta, Stockholm, Sweden) were satisfactorily positioned, they 
were locked into position using template screws. Following this, high-resolution two-
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dimensional T2-weighted images (FOV 140 mm, TR 4000 ms, TE 100 ms, matrix 320 x 320, 
voxel resolution 0.4 x 0.4 x 2.0 mm, three averages) were acquired for the treatment planning. 
These images were exported to the treatment planning software (Oncentra Masterplan, Elekta, 
Crawley, United Kingdom).  
After the acquisition of the treatment planning images, the obturators were replaced inside the 
brachytherapy catheters, and the patient was transferred into HDR treatment vault by 
undocking the MR table from the scanner without the need to move the patient.  
Clinical target volume included the prostate and a 2-mm margin beyond gross visible disease 
(GTV) on MRI, excluding urethra, rectum, and bladder. Planning target volume (PTV) 
included the clinical target volume plus 1 mm superior/inferior to account for the uncertainties 
introduced with slice thickness volume averaging. Urethra, bladder, and rectum were 
delineated as solid organs-at-risk (OARs).  
 
4.4. HDR brachytherapy planning and treatment details  
 
HDR brachytherapy dose prescription migrated from a standard-care approach of two fractions 
(10 Gy each) in two separated implants, to a single fraction implant (15 Gy) during the course 
of the study. This change was reflection of adoption of Canadian regimen of hypofractionated 
EBRT (37.5 Gy in 15 fractions with 2.5 Gy dose per fraction) combined with single HDR 
implant of 15 Gy once this approach was shown to be effective and has favorable quality-of-
life profile (115,153,154).  
A brachytherapy plan was generated using inverse planning to meet dose objectives based on 
Radiation Therapy Oncology Group (RTOG) and Toronto (Odette Cancer Centre at 
Sunnybrook Health Sciences Centre) experience (98)(Dr. Morton Personal Communication: 
V100≥95% of prostate volume V90≥98% of prostate volume, Urethral D10≤117% (17.5 Gy), 
Rectal V80<0.5 cc). 
Our dose objectives included PTV V100>95%, PTV V150<50%, rectal V75<1 cc and V80<0.5 
cc, urethral V125<0.5 cc, bladder V75<1 cc. Additional effort was made to encompass GTV 
(gross tumor volume) by prescription dose (priority objective). 
Lateral C-arm X-rays were acquired immediately before delivery of treatment, and off-set 
correction was applied if catheter displacement greater than 3 mm was identified. Treatment 
was delivered using multichannel MicroSelectron afterloader (Elekta). Patients were 
discharged home the same day after successful voiding. 
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4.5. EBRT treatment details  
 
One week following HDR brachytherapy implant, patients started EBRT portion of the 
treatment. EBRT dose for intermediate risk patients was 37.5 Gy delivered in 15 fractions to 
the prostate alone and 1 cm of proximal seminal vesicles and 46 Gy in 23 fractions to the pelvis 
for high-risk patients. EBRT was delivered using a 4-field conformal technique or IMRT. The 
PTV (Planning Target Volume) was a uniform 1 cm expansion beyond the CTV (Clinical 
Target Volume). PTV received ≥95% of the prescription dose, prescribed at the isocentre.   
 
4.6. Patient follow-up 
 
Patients were followed prospectively at 1, 3, and 6 months and 1, 2, 3, and 5 years after 
brachytherapy. 
Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 
4.0 (155). Early toxicity was defined if occurred within 3 months after the procedure, whereas 
late toxicity was defined if occurred more than 3 months after the procedure. Health-related 
quality of life was assessed by the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire, with urinary symptoms level assessed by International Prostate Symptom Score 
(IPSS). Both EPIC and IPSS questionnaires are recognized, validated and widely 
acknowledged instruments for assessing symptom burden and quality-of-life of patients with 
PCa receiving curative treatment (156,157).    
 
4.7. Statistical considerations  
 
This was an exploratory feasibility study which aimed to provide estimates of variance in the 
data. Numerical indices and values were presented either with average and standard deviation 
or median and range. Kolmogorov-Smirnov test was used to assess normality of the data 
distribution. Change in overall procedure duration over course of time was assessed by linear 
regression.     
Prostate-specific antigen (PSA) relapse-free survival is measured from the date of the 
brachytherapy implant to the date of confirmed biochemical failure, which is assessed using 
Phoenix definition (nadir+2) (158). Patients without biochemical failure were censored at the 
date of last follow up. PSA relapse-free survival and metastasis-free survival were assessed 
using Kaplan-Meier method. Change in IPSS and EPIC summary scores were assessed in 
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comparison with baseline scores using Wilcoxon-signed rank test with Bonferroni correction 
for multiple testing.  
Statistical analysis was performed using MedCalc for Windows, version 13.0.6.0 (licensed 
MedCalc Software, Ostend, Belgium), with p-value less than 0.05 considered statistically 
significant.  
 
5. RESULTS  
 
5.1. Patient and tumor characteristics  
 
Patient’s and tumor characteristics are presented in Table 9.  
 
Table 9. Patient’s and tumor characteristics 
N of patients 40 
Median age (range) 68 (49-78) 
Median PSA (range) 13.1 (3.1-117.0) 
Gleason score, N (%) 
 
      7 25 (62.5) 
      8 6 (15.0) 
      9 9 (22.5) 
Clinical stage*, N (%) 
 
     cT1c 8 (20.0) 
     cT2a 8 (20.0) 
     cT2b 3 (7.5) 
     cT2c 7 (17.5) 
     cT3a 9 (22.5) 
     cT3b 5 (12.5) 
Risk category, N (%) 
 
      Intermediate-risk 11 (27.5) 
  
42 
 
      High-risk  29 (72.5) 
Androgen deprivation therapy, N (%) 25 (62.5) 
Median IPSS (range) 4 (0-18) 
Median prostate volume in cc (range) 34 (17-81) 
Median MRI max. tumor diameter in cm (range) 1.2 (0.5-3.8)  
Tumor findings on MRI, N (%)  
       No tumor 8 (20.0) 
       One tumor 23 (57.5) 
       Two tumors 7 (17.5) 
       Three tumors 1 (2.5) 
       Four tumors  1 (2.5) 
Dominant tumor location (%)  
      Anterior zone 9 (28.1) 
      Posterior zone  23 (71.9) 
PSA=prostate-specific antigen, IPSS=International Prostate Symptom Score  
*staging included imaging data both from staging MRI (when available) and interventional 
MRI   
 
Between January 2010 and March 2015, 40 patients were enrolled to receive whole gland 
prostate HDR brachytherapy combined with EBRT under MRI guidance on a prospective 
clinical trial approved by institutional research ethics board 
(https://clinicaltrials.gov/ct2/show/NCT00913939). Median patient’s age was 68, and median 
PSA was 13.1. Majority of patients had Gleason 7 PCa and had initial T1-T2 stage. Majority 
of patients had high-risk disease and 25 patients (62.5%) received androgen deprivation 
therapy. Median IPSS was low (4), indicating low lower urinary tract symptom burden among 
the included patients. Median prostate volume was of average size (34 cc). Median of patient’s 
follow-up of was 30 months (range, 6-61 months). 
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5.2. Overview of the implant procedures  
 
In total, 62 implants were performed. The first 22 patients had two separate HDR implants of 
10 Gy each, and the subsequent 17 patients had a single 15 Gy implant. One patient received a 
single 10 Gy implant. He developed acute urinary retention immediately afterwards and was 
not eligible for the second implant. One patient received a first implant with a dose of 10 Gy, 
and the second implant with 11.5 Gy for gross seminal vesicle involvement found on 
interventional MRI. This case was very illustrative, has a teaching point on relevance of 
interventional MRI scans, and is presented on Figure 10.  
 
 
 
  
Figure 10. Example of the case with seminal vesicle invasion (up-staged to T3b disease based 
on interventional MRI scans). Patient presented with intermediate-risk prostate cancer (clinical 
T2a, Gleason score 3+4, iPSA 12). Right seminal vesicle involvement was revealed at the time 
of HDR brachytherapy. On left panel is T2-weighted pre-implant MRI with arrow indicating 
gross seminal vesicle involvement; middle panel is showing catheters implanted anteriorly to 
the tumor. Right panel indicate successful implantation of the catheter (black signal void) in 
the center of the tumor.     
 
 
5.3. MR imaging observation   
 
At the moment of the HDR brachytherapy, interventional MRI scans upstaged 14 patients 
(35%) who were found to have a higher stage of disease than initially perceived on clinical 
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staging (based on digitorectal examination and TRUS) – Table 10. Six patients from this group 
required insertion of brachytherapy catheters outside of the prostate boundary to address gross 
extracapsular disease extension (N=2) or seminal vesicle invasion (N=4). Case example 
illustrating implantation of locally advanced disease with extracapsular extension is depicted 
on Figure 11.  
 
 
Table 10. Change in patient’s clinical stage based on MRI scans at the time of brachytherapy. 
Note 14 patients were restaged and found to have a higher stage of disease. In 6 patients, this 
change in stage impacted management (change in brachytherapy volumes and/or addition of 
hormonal therapy based on the migration to high-risk group).  
 
  Staging based on interventional MRI  
  cT1c cT2a cT2b cT2c cT3a cT3b Total 
S
ta
g
in
g
 
b
as
ed
 
o
n
 
D
R
E
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d
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r 
T
R
U
S
*
 
cT1c 8 4 / 3 / 3 18 
cT2a / 3 / / 2 / 5 
cT2b / / 2 1 / / 3 
cT2c / / / / / 1 1 
cT3a / / / / 1 / 1 
cT3b / / / / / 1 1 
Total  8 7 2 4 3 5 29 
DRE=digitorectal examination; TRUS=transrectal ultrasound.  
*11 patients who had baseline MRI staging scans were excluded from this analysis.  
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Figure 11. Example of extracapsular extension (MRI T3a). Patient initially presented with 
high-risk prostate cancer with known T3a disease before the brachytherapy. Left panel (a): T2-
w MRI before first implant showing gross extracapsular extension (arrow). Middle (b): implant 
with isodose plan (blue line=75% isodose, pink line=100% isodose). Note complete coverage 
of extraprostatic disease with 100% isodose). Right (c): MRI before the second implant. Note 
significant reduction in extraprostatic disease in response to treatment. This enabled reduced 
rectal dose exposure. Second row (d): Example of large locally advanced prostate cancer. (e): 
MRI guidance allowed implantation of the large right-sided extraprostatic tumor abutting the 
rectum.     
 
 
Most patients (N=32, 80%) were found to have at least one tumor (scored using PIRADS 
version 2.0 as 4 or 5) (138). Median maximum tumor diameter was 1.2 cm (range 0.5-2.9 cm). 
Nine patients had gross multifocal disease with more than one tumor identified. Tumors were 
located anteriorly in 11 patients (28%).  
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MRI before catheter insertion was essential for tumor staging and GTV delineation. It also 
assisted in segmentation of the prostate apex for treatment planning, whereas MRI acquired 
after catheter insertion provided highly resolved anatomic boundaries and clear catheter 
signatures for accurate treatment planning. See example in Fig. 12.  
 
 
 
 
Fig. 12. Provided is typical example of posterior tumor. On the left: tumor in right peripheral 
zone (arrow) abutting the rectum. Right: subsequent HDR brachytherapy dose plan. 
Prescription isodose-100% (pink) covers tumor whereas prostate gland coverage is 
compromised contralaterally in non-tumor bearing regions to reduce rectal dose. This is 
illustration of dose painting and sculpting enabled by the MRI-targeted HDR brachytherapy. 
Note that tumor is not clearly visualized after catheter placement due to bleeding and edema.   
 
 
 
Blurring of the prostate apex boundary after catheter insertion which was related to pelvic 
hematoma caused by needle trauma, was observed in all cases and is illustrated in Fig. 13.  
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Fig. 13.  Illustration indicate typical example of the blurring of the apical prostate boundary 
after the insertion of catheters secondary to oedema and bleeding. Note brighter T2-w signal in 
levator ani muscle as a result of trauma.  
 
 
 
5.4. Workflow efficiencies  
 
Median time for patient setup was 25 minutes (range, 14-78 minutes). This included induction 
into intravenous anesthesia, patient positioning on interventional MRI tabletop, insertion of 
endorectal coil and perineal template, positioning of body coils, and MRI scout imaging for 
registration of devices. Median duration of the interventional procedure (catheter insertion plus 
all imaging time) was 100 minutes (range, 51-357 minutes). Median overall anaesthesia time 
was 4.0 hours (range, 2.1-6.9 hours). A learning curve was evident with trends for improved 
efficiency over time (Fig. 14). Median number of catheter used was 15 (range, 9-18).  
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Fig. 14. Regression analysis of overall implant procedure time over the course of the study 
showing trend towards improved efficiency with shortened overall procedure time (p for slope 
<0.0001).  
 
 
 
 
5.5. Dosimetric outcomes 
 
Dosimetry data are presented in Table 10. Median PTV volume was 34.8 cc (range, 16.8-84.7 
cc). Median PTV V100 was 95.8% (range, 81.5-99.4%), whereby PTV V100 was ≥95% in 47 
procedures (76%) and PTV V100>90% in 60 procedures (97%) (Fig. 15). Prostate D90 
between 105% and 115% of prescribed dose was achieved in 82% of procedures. PTV coverage 
was typically compromised in non-tumor-bearing regions to improve rectal dose exposures 
(see example in Fig. 11). Rectal doses ranged widely, and dose planning objectives were not 
met in 48 of 62 implants (77%), mainly due to the proximity of the anterior rectal wall at the 
mid-gland and apical levels against the posterior prostate boundary (see example in Fig. 12).  
Rectal V75<1 cc was achieved in only 21% of procedures (Fig. 16). Urethral doses were low 
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and in only one implant exceeded our dose-planning objectives, whereas bladder dose 
objectives were met in all 62 implants. Prostate V150≤40% was achieved in 42% of procedures 
and ≤50% in 98% of procedures (Fig. 17). This large high-dose volume was attributed to a 
catheter implantation approach that favored catheters to be placed a few millimeters medial to 
the prostate capsule, rather than immediately at the capsule, to improve catheter visualization, 
intensify prostate dose, and improve dose conformity.  
 
Table 10.  HDR dosimetry data  
Parameter Median value (range) 
PTV dose metrics   
       PTV volume   34.8 (16.8-84.7) cc 
       V100 95.8 (81.5-99.4) % 
       V150 40.7 (25.0-59.7) % 
       V200 16.9 (11.2-30.1) % 
       D90 108.6 (94.4-118.0) % 
Urethral dose metrics   
       V125 6.9 (0-65.0) % 
       V115 46.7 (1.2-73.0) % 
       V105 68.7 (19.0-99.0) % 
       D0.5cc 115.3 (97.4-136.4) % 
       D10 123.6 (109.8-145.3) % 
       Maximum point dose  144.0 (126.0-262.0) % 
Rectal dose metrics   
       V75 3.0 (0-11.8) % 
       V75 (cc) 1.6 (0-6.1) cc 
       V80  1.9 (0.1-8.3) % 
       V80 (cc) 1.0 (0.1-4.2) cc 
       D0.5cc 85.2 (58.8-95.2) % 
       Maximum point dose 103.8 (73.6-228.4) % 
Bladder dose metrics   
      V75 5.0 (0.2-24.1) % 
      D0.5 cc 90.2 (63.4-116.4) % 
      Maximum point dose 151.8 (86.8-312.6) % 
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Figure 15. Achieved V100 for PTV (PTV volume covered by 100% of prescribed dose) for 
each HDR implant plotted against the number of HDR implants performed. Red line represents 
our planning aim of >95%.    
 
 
 
Fig. 16. Achieved V150 for PTV (PTV volume covered by 150% of prescribed dose) for each 
HDR implant plotted against the number of HDR implants performed. Red line represents our 
planning aim of <50%.    
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Fig. 17. Achieved Rectal V75(cc) (rectal volume in cc covered by 75% of prescribed dose) for 
each HDR implant plotted against the number of HDR implants performed. Red line represents 
our planning aim of <1 cc. Note that in many implants this planning aim was not met.     
 
 
5.6. PSA and clinical outcomes outcomes  
 
At median follow-up of 30 months, 3 patients (7.5%) experienced biochemical failure 16, 30, 
and 39 months after completion of treatment, respectively. Two of these patients also 
developed widespread bone metastases shortly after experiencing biochemical failure; 1 patient 
later developed castrate-resistant disease and is currently receiving docetaxel chemotherapy, 
whereas the second patient continues to have hormone-sensitive disease. Three patients who 
failed treatment had unfavourable pre-treatment characteristics, including seminal vesicle 
invasion, extraprostatic tumor extension of Gleason score (GS) 4+5 disease, seminal vesicle 
involvement of bulky GS 3+4 tumor, and bilateral GS 3+4 tumor with initial PSA 10.6, 
respectively. On the review of the implant dosimetry in those patients, no impaired target 
coverage was identified.        
Biochemical relapse-free probability at 3 years was 91.7% (95% confidence interval: 85.0-
97.4%). One patient died from stroke 18 months after the procedure, which was not related to 
either treatment or prostate cancer recurrence.     
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5.7. Toxicity and health-related quality of life  
 
Two patients (5%) experienced Grade 3 toxicity. One patient experienced Grade 3 acute 
urinary retention and hematuria that required hospitalization following the HDR brachytherapy 
implant of 10 Gy. His intra-procedural MRI scans were later reviewed, and on the needle 
insertion images, urethral trauma was revealed. Other patient developed Grade 3 urethral 
stricture in the proximal bulbar urethra 4 months after the procedure. Again, careful review of 
treatment planning images identified urethral trauma at the level inferior to the prostate. This 
stricture was successfully corrected with urethral dilatation and the patient remained in good 
urinary function thereafter.  
 
Eight patients (20%) developed Grade 2 acute urinary toxicity, whereas there was no acute 
Grade 2 gastrointestinal toxicity. Six patients (15.0%) experienced late Grade 2 urinary 
toxicity. Three patients (7.5%) experienced late Grade 2 gastrointestinal toxicity attributed to 
the EBRT component.      
 
Changes in IPSS from baseline to follow-up levels are presented in Fig. 18. Statistically 
significant increase in IPSS was observed at the 1-month, 3-month, 6-month, and 1-year 
follow-up (Bonferroni corrected p<0.001, p=0.014, p=0.021, and p=0.021, respectively), 
whereas at 2-year and 3-year follow-up this difference was not significant (p=0.37, p=1.0, 
respectively).  
Changes in EPIC summary scores from baseline to follow-up levels are presented in Fig. 19. 
Statistically and clinically significant decrease was observed in EPIC urinary and bowel 
summary scores during the first year after the treatment. Change in urinary summary scores, 
bowel summary scores, and sexual summary scores as compared with baseline scores were not 
statistically different at 1-, 2-, and 3-year follow-up, respectively. Low sexual summary scores 
were reflective of high use of androgen deprivation therapy (62.5% of patients).       
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Fig. 18. Change in IPSS from baseline over time  
(IPSS=International Prostate Symptom Score, CI=confidence interval) 
 
 
 
Fig. 19. Changes in EPIC summary scores from baseline over time  
(EPIC=Expanded Prostate Cancer Index Composite, CI=confidence interval)  
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6. DISCUSSION 
 
Main finding from this prospective study is that MRI-guidance of HDR brachytherapy boost 
for PCa is feasible and safe. This conclusion was established on sufficient number of patients 
showing added benefit of having MRI both for on-line guidance of brachytherapy catheter 
insertion and for treatment planning. However, the steep learning curve was evident but with 
more experience work-flow efficiency was significantly improved and the procedure was 
subsequently completed within 3-4 hours.      
Several important advancements were implemented into our technique of MRI-guided HDR 
brachytherapy which was initially reported in 2004 as first use of MRI as image guidance tool 
for prostate HDR brachytherapy (148). Technique has evolved from lateral decubitus to a frog-
leg position, from ventilated to non-ventilated anesthesia, from 1.5T to 3T systems, and from 
prototype to commercialized device (Fig. 6.). Interventional MRI is highly resource-intensive 
program, occupying MRI brachytherapy suite almost for a whole shift and colliding with other 
increasing demands for MRI scanner in busy radiotherapy department. Therefore, our program 
initially focused on a tumor-targeted approach in the salvage setting for failure after previous 
radiotherapy. Subsequently, our program expanded to include patients receiving standard-care 
HDR brachytherapy prostate boost to EBRT.  
In this study, we used an MRI-only work flow, implicating that MRI was used both for catheter 
navigation, insertion and for treatment planning. Patient stayed on movable table top during all 
procedure, without changing position, but was transported from MRI suite to brachytherapy 
suite for treatment delivery.  
With this prospective phase II study, we continue to show that MRI guidance is a feasible and 
safe approach for delivering HDR brachytherapy whole gland boost for prostate cancer. No 
major toxicity was observed and patient’s quality of life although initially decreased, in further 
follow-up normalized back to the baseline levels. Incidence of late Grade 3 genitourinary 
toxicity is very low at 2.5%, what is on lower end of observed toxicities in other reports with 
similar risk-group patient population. Furthermore, early oncologic outcomes are very 
encouraging. Biochemical recurrence-free survival of 92.5% is in keeping with other reports 
for similar intermediate- and high-risk population (Table 6.). However, these results should be 
interpreted with caution because of short follow-up (median 30 months), differential use of 
androgen deprivation therapy compared to other studies and relatively small patient sample 
size.    
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The main limitations to broader acceptance of this pure-MRI approach are intensive workflow-
related burden and limited access to MRI in general and particularly to interventional MRI in 
majority of radiotherapy centres.                  
We demonstrated with the use of interventional MRI that significant proportion of patients had 
disease extending beyond the prostate boundary, something that was unnoticed at the initial 
presentation using routine clinical staging such as digitorectal examination and TRUS. Those 
patients required a more targeted catheter implantation and dose-planning strategy to prevent 
marginal miss. It is clear that TRUS-guided approach in this setting would result in 
unappreciated and underestimated disease that would be left untreated leading to major target 
miss and potential treatment failure.  
Our experience is comparable to that reported in EBRT literature where additional imaging 
information obtained from MRI scans changed treatment coverage in up to 20% of patients 
(159).    
We defined our dose-planning objectives based on TRUS- or CT-based HDR brachytherapy 
data using published literature (160,161) and found that those dose criteria did not readily 
translate when using our MRI-based approach.  
Basically, we were not able to meet rectal dose-planning objectives in many cases. There might 
be some potential explanations for that. First, MRI very clearly depicts the rectal wall and 
posterior prostate boundary, whereby there is little if any uncertainty in delineation compared 
with TRUS and CT. In our experience, the rectal wall was consistently closely abutted to the 
prostate gland from the apex to the midgland. It might be possible that the rectal wall is under 
contoured (or underestimated) on CT and TRUS in the absence of clear visualization. 
Alternatively, it is also possible that the endorectal imaging coil is positioned in such manner 
that applies anterior displacement of the rectal wall compared with the conventional TRUS 
probe setup. Second, in our anesthesia approach, we used intravenous propofol anesthesia 
without muscle relaxants what might have led to increased tone of pelvic floor musculature 
that possibly brings closer prostate and the rectum. Furthermore, in TRUS-guided procedure 
legs are in the lithotomy position sustained by leg supporters, while in MRI-guided procedure 
legs are on the table, in the frog-leg position. This could also have impact on pelvis floor 
muscles and rectal-prostate boundary.     
It is reassuring, though, that we have not observed any rectal toxicity to date despite more 
adverse dosimetric indices. Challenges with rectal dose exposures resulted in lower PTV 
coverage outside tumor-bearing regions of the prostate. It is premature to determine whether 
PSA or local control outcomes were consequently compromised, but our present results are 
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encouraging. Finally, we generally observed larger high-dose volumes stemming from a 
deliberate strategy of implanting all catheters well within the periphery of the gland, with no 
evident clinical implications to date.     
Two cases of transient Grade 3 genitourinary side-effects were observed, both related to 
incurred urethral trauma at the time of implantation, as confirmed on interventional MR 
images. One patient had acute urinary retention caused by blood coagulum in the bladder, while 
the other developed stricture in bulbar urethra. First patient required short hospitalization, 
bladder catheterization and irrigation and soon was discharged home with spontaneous voiding. 
Second patient underwent ambulatory urethral dilatation which was successful and the patient 
remained well with no obstructive urinary issues.    
Incidence of acute urinary retention varies between different HDR brachytherapy boost series 
and heavily depends on fractionation protocol used. In Canadian prospective trial by Morton 
et al. from Sunnybrook which enrolled 123 patients who were receiving EBRT of 37.5 Gy in 
15 fractions combined with single HDR boost dose of 15 Gy, only 2 patients (1.6%) 
experienced acute urinary retention requiring catheterization. On other hand, in the two HDR 
fractions protocol, which accrued 60 patients, 12 patients (20%) experienced acute Grade 3 
urinary retention (115).  
However, comforting is that the majority of acute retention episodes are transient events which 
completely resolve after patients having catheter inserted for couple of days.      
Urethral strictures are the most important and the most common serious late genitourinary side-
effects associated with HDR brachytherapy. Incidence of Grade ≥2 strictures reported in HDR 
brachytherapy literature range from less than 1% to alarming 30% (109,162–164). However, 
realistic rate of urinary strictures in contemporary series is probably below 10% and is 
associated with fraction size and unintended high-radiation exposure of the external sphincter 
and bulbo-membranous urethra while delivering full dose to the prostate apex (165). In the 
work by Hindson et al. on 345 patients treated with EBRT and 3 different HDR brachytherapy 
boost fractionations (20 Gy/4x, 18 Gy/3x, and 19 Gy/2x) during three sequential time periods 
with CT-based planning, overall stricture rate was 12.7%, and overall risk of stricture formation 
at 2 years was 8.2%. The highest stricture risk (31.6%) was in the group of patients that received 
HDR boost of 19 Gy in 2 fractions. Majority of strictures were located in the bulbomembranous 
urethra (50%) or external sphincter region (33%). On multivariable analysis the only significant 
predictor for increased stricture formation was dose schedule used (164). The largest analysis 
of strictures issue following HDR brachytherapy boost to EBRT is the work by Sullivan et al. 
on 474 patients using multiple HDR fraction schedules. Thirty-eight patients (8%) were 
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diagnosed with a urethral stricture leading to 6-year actuarial risk of 12%. The overall actuarial 
rate of Grade≥2 urethral strictures was estimated to be at 10.8%, with the median time to 
diagnosis of 22 months. Dominant stricture location was bulbo-membranous urethra (92.1%). 
Most common initial management included dilatation or optical urethotomy, however second 
and third line salvage therapy was required in 49%, and 9% of cases, respectively. On 
multivariate analysis, predictive factors for stricture formation were prior TURP and, as in the 
previous study, HDR dose per fraction (163).     
In our experience, needle trauma was presumable causative factor for development of serious 
genitourinary side-effects. This comes as no surprise, as needle trauma is factor known to be 
associated with development of urinary toxicity following HDR brachytherapy. In a study by 
Boyea et al. from William Beaumont Group on 37 patients receiving HDR monotherapy, 
investigators found that increased number of attempts to satisfactorily position the needles was 
associated with development of urinary toxicity (166). Possible explanation of this toxicity is 
probably related to increased prostate oedema caused by repetitive needle insertion and 
manipulation. 
 
In this study, several features unique to an MRI-only workflow were observed. First, we found 
that ¾ of all patients had either one of two prostatic tumor(s) within the gland. Prostate cancer 
is often multifocal disease, as data from historical prostatectomy series indicate (167). 
Contemporary use of MRI enables visualisation of tumor lesions and evaluation of their clinical 
significance. Furthermore, MRI allowed new avenues of treatment enabling boosting the 
dominant intraprostatic lesion, which is often the site of local recurrence after EBRT (168). 
There is growing interest to boost imaging-identified intraprostatic disease and several ongoing 
trials are trying to address feasibility and utility of this concept (169). However, there is no 
consensus on GTV definition and boost dose. Boost dose could be delivered either with HDR 
brachytherapy (10 Gy) or IMRT/VMAT technique (95 Gy in 38 fractions to GTV) as in 
TARGET study led by Dr. Ménard (study number NCT01802242). Regularly during HDR 
implant procedure it is possible to place catheters in the core of the tumor (Fig. 10) so the lesion 
can be encompassed by area of very high dose (usually within 200% isodose). HDR 
brachytherapy whole gland boost routinely employs the principle of boosting the dominant 
intraprostatic nodule as per regular workflow.     
In a recent report by Spanish brachytherapy group aiming to demonstrate feasibility, safety and 
effectiveness of intraprostatic dose escalation using HDR brachytherapy,  15 patients with 
intermediate or high risk PCa with MRI detected dominant intra-prostatic nodule (DIL) were 
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treated with HDR boost using combined MRI-TRUS fusion for image guidance (170). They 
showed that dose escalation to DIL was feasible in 14 patients, where the dose of 18.75 Gy 
(125% of the prescribed dose) was successfully delivered to at least 98% of the DIL volume 
(D98%≥18.75 Gy).  Authors showed encouraging results for technique where TRUS images 
were registered with diagnostic MRI for purpose of needle insertion and planning, allowing 
fair partial prostate dose escalation. Using our pure MRI technique, which brings 
unprecedented accuracy and precision compared to TRUS-MRI fusion, we were able to 
escalate dose to the intraprostatic tumor even further. In our experience, DIL would be often 
encompassed by 200% isodose curve, as the needles were deliberately positioned in the core 
of the DIL allowing safe extreme dose escalation to the tumor. This was not possible only in a 
case when the DIL was in the vicinity of the rectum.           
 
In our study, we identified tumors in the anterior aspect of the gland in almost a third of patients.  
As previously discussed, MRI is capable to discern zonal anatomy of the prostate, which is 
based on the seminal work by McNeal, who described prostate regional architecture (171). 
According to that concept, prostate is made up of anterior fibromuscular stroma, and three 
distinct glandular zones: peripheral zone (located posteriorly and inferiorly), the central zone 
(located anteriorly), and the transitional zone (located centrally and medially) (Fig. 20).      
 
 
 
Fig. 20. Zonal anatomy of the prostate (reproduced with permission from Prostadoodle.com, 
courtesy by Dr. Patrick W. McLaughlin).    
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Although cancers of the anterior prostate (part of the prostate anterior to the urethra) account 
for approximately 20% of all prostate cancers, they are often undetected using classical TRUS-
guided biopsy as anterior prostate biopsies are excluded from standard sextant biopsy templates 
(172). Most of the data on anterior prostate cancer comes from the surgical series with whole 
mount pathology. Those data suggest that anterior prostate cancers have lower Gleason score 
and lower rates of extraprostatic extension, however they come with higher overall tumor 
volume and higher rates of positive surgical margins (173). Their clinical behaviour is not well 
understood although reports indicate that despite adverse pathological features associated with 
anterior cancers, those cancer have similar clinical outcomes compared to more prevalent 
posterior cancers  (174).  
Radiotherapy dose is frequently compromised in the anterior prostate region under presumption 
that cancer cell are predominantly located in the peripheral zone. However, awareness of the 
tumor location in anterior prostate, as revealed using interventional MRI, augments the dose 
distribution and planning aiming to cover all visible disease, avoiding marginal miss.     
We also noted blurring of apical prostatic boundary after insertion of catheters and brightening 
of T2 signal in levator ani muscles resulting from needle trauma (Fig. 12).  
This observation highlights the importance of having access to MR images acquired before 
catheter insertion to aid accurate delineation of the prostatic apex. The most important image 
acquired throughout the procedure is the image acquired before catheter insertion. An 
alternative strategy would be to obtain a diagnostic MRI scan before the brachytherapy 
procedure and to either cognitively (175) or computationally register that image to 
interventional TRUS images (using deformable registration software). However, it is 
challenging to achieve high registration accuracy in the context of highly deformable target 
and minimal common imaging structure, especially after catheter insertion which alters 
anatomical relations. Although some commercial solutions have been developed for three-
dimensional fusion of diagnostic MR and TRUS, at present they are far from optimal 
(176)(177).  
This can be particularly relevant in the context of steep dose gradients inherent to HDR 
brachytherapy, as opposed to TRUS-guided diagnostic biopsies for which these solutions have 
been mainly developed and tested (178). 
Acquiring MR images both before and after a TRUS guided implant may mitigate these issues 
but introduces other potential workflow inefficiencies to the process. An MRI-only workflow, 
improved through better computation strategies and the integration of robotics (179,180), 
remains an appealing strategy.        
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In this study described MRI-only workflow bring unprecedented precision and customization 
in the process of image guidance and dose planning of prostate HDR boost. However, it does 
come with significant associated costs and high resource utilization. This technique requires 
dedicated MRI access and the crew of highly trained staff who operate scanner and assist in 
needle navigation and insertion. Although we observed trend of improved procedure efficiency 
over time, in majority of cases procedure duration is still more than 3 hours. Similarly, steep 
learning curve and recent trends for shortened procedure time was observed in TRUS/MRI 
combined prostate HDR program by Aarhus group (Denmark), where average procedure 
duration time from starting average 7.6 came down to 5.3 hours in more recent procedures 
(181).   
In addition, an anaesthesia team was always present throughout the duration of the procedure. 
Furthermore, all equipment in the room must be MRI safe, including needles, anaesthesia 
equipment, stretchers, carts, cameras, monitors, etc. which brings additional significant costs.   
 
Our study has certain limitations that should be acknowledged. Our short patient follow-up 
(median 30 months) and modest sample size limit our observation regarding clinical outcomes 
(biochemical control and metastasis-free survival) and prevent drawing conclusion on long-
term efficacy and toxicity profile of our treatment protocol. In addition, migration of standard 
dose prescription practices (both for EBRT and HDR components of the treatment) through 
the course of the study resulted in a heterogeneous radiation treatment across the cohort. 
Optimally, dose-summation analysis using deformable image registration in a larger cohort of 
patients may better identify relationship between dose metrics and patient outcomes.    
 
 
7. CONCLUSION  
 
In this study we found that an MRI-only workflow for prostate HDR brachytherapy revealed 
the influence of images acquired throughout the course of the procedure toward improving 
tumor coverage and overall implant quality. An MRI-only workflow is feasible and safe and 
justified in patients with large tumor burden but must be streamlined for broader acceptance 
given its high resource utilization. One way to improve efficiency of the procedure would 
potentially be dual imaging modality use: TRUS for needle insertion guidance and MRI for 
treatment planning. In this scenario, MRI could be acquired following TRUS-guided needle 
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implantation to facilitate improve dose optimization for HDR brachytherapy. However, it 
remains to be seen whether this concept is clinically feasible.     
 
8. FUTURE DIRECTIONS  
 
MRI-guided brachytherapy remains attractive concept in both in LDR and HDR brachytherapy 
for prostate cancer. However, it is hard to predict how the role of MRI will entails in HDR 
brachytherapy given very high level of complexity and intense resource utilisation associated 
with interventional MRI. Added benefit of MRI in whole gland boost might be less critical 
compared with role of MRI guidance in focal treatment (either for salvage after previous EBRT 
or targeted dose escalation to dominant intraprostatic lesion or upfront partial gland treatment). 
Recent study from Princess Margaret Cancer Centre prostate brachytherapy group presented 
dosimetric feasibility of focal dose-escalated HDR monotherapy. In this dosimetric study it 
was found feasible to escalate the dose both to intraprostatic PTV (33-36 Gy) and GTV (40 
Gy) in two fractions respecting predefined OAR constraints. Additionally, in almost half of the 
investigated cases it was possible to achieve single-dose treatment of 24 Gy to PTV (182). 
Although focal therapy concept definitively needs to be assessed in rigorously conducted 
prospective trial, these preliminary dosimetric results remain encouraging. Potential candidates 
for focal approach would probably be patients with unifocal gross disease (MRI-defined lesion) 
in lower risk group.   
Advent of new technologies can further augment precision of MRI-guided brachytherapy and 
streamline its flow. Introduction of robotics in this field has already been tested (180,183) with 
encouraging results. Given accessibility problem in interventional MRI scanner in regards to 
needle insertion, this part of procedure could be performed by the MRI-compatible robot. 
Current strategy is being tested in Nijmegen, Netherlands.  
Other avenues of research which could impact MRI-targeted brachytherapy are integration of 
TRUS with MRI in order to simplify implant procedure. Such dual-imaging modality offers 
potential for improving efficiency of the implant procedure and overcoming of shortcomings 
of each single imaging modality. As previously discussed, one potential explication of 
inefficiencies of intraoperative MRI guidance could be integration of TRUS for intraoperative 
catheter guidance and subsequent MRI-TRUS fusion. However, caution should be exerted 
here, as there is always potential for significant error given imperfect image fusion. To 
overcome this issue, different deformable registration software solutions have been developed 
including our in-house program (Morfeus). This is a biomechanical-model based deformable 
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registration algorithm which takes into account elastic registration of prostate MR based on 
estimation of deformation states between two imaging points (i.e. fusion of diagnostic MRI or 
simulation MRI with planning MRI with implanted prostate) (184).  
More work remains to be done in area of MRI sequence optimization and imaging efficiency 
with aim of acquiring highest quality images in shortest time frame to reduce procedure length, 
improve clinical workflow and decrease treatment-related burden while optimizing cure rates 
and maintaining high quality of life.   
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9. SAŽETAK - ABSTRACT IN CROATIAN  
 
UVOD: Brahiterapija velikom brzinom doze je metoda izbora u visokodoznom zračenju raka 
prostate. Magnetska rezonanca (MR) pruža visoku slikovnu rezoluciju mekih tkiva i teoretski 
može poslužiti kao odlično sredstvo slikovnog navođenja brahiterapije velikom brzinom doze.   
BOLESNICI I METODE: Četrdeset (40) bolesnika s rakom prostate srednjeg ili visokog 
rizika uključeno je u prospektivnu kliničku studiju koju je odobrilo etičko povjerenstvo 
ustanove Princess Margaret Hospital. Multiparametrijska MR sa stereotaksijskom navigacijom 
je korištena u svrhu navođenja brahiterapijskih katetera, nakon čega je uslijedilo planiranje 
zračenja na osnovi MR.   
REZULTATI: U okviru studije provedena su 62 brahiterapijska implanta. Medijan vremena 
potrebnog za inserciju katetera i oslikavanje bio je 100 minuta, dok je cjelokupno vrijeme 
trajanja anestezije bilo oko 4.0 sati (raspon 2.1-6.9 sati). MR korištena za vrijeme brahiterapije 
otkrila je da je u 14 (35%) bolesnika viši stadij bolesti nego što se prethodno smatralo. U 6 
bolesnika ovo saznanje je koristilo u ciljanom navođenju brahiterapijskih katetera izvan granica 
prostate: slučaj ekstrakapsularnog širenja u 2 bolesnika te širenje bolesti u sjemene mjehuriće 
u 4 bolesnika. Većina bolesnika (80%) je imalo vidljiv tumor uočljiv na MR, koji je utjecao na 
raspored razmještanja katetera i planiranja zračenja. MR je opisao anatomske granice jasno 
nakon provedene implantacije, osim u slučaju apeksa prostate koji je bio zamagljen prisutnom 
krvlju nakon insercije katetera. Konvencionalna ograničenja doze za pokrivanje PTV (PTV 
V100>98%) i za rektum (V75<1.0 cc) bilo je teško zadovoljiti, no toksičnost metode je bila 
mala (akutna genitourinarna toksičnost većeg ili jednakog stupnja od 2 bila je 20%, kasna 
genitourinarna toksičnost većeg ili jednakog stupnja od 2 bila je 15%, kasna gastrointestinalna 
toksičnost većeg ili jednakog stupnja od 2 iznosila je 7%). Mehaničko oštećenje uretre viđeno 
na MR dovelo je do dvije ozbiljne nuspojave gradusa 3, koje su bile prolazne prirode.  
ZAKLJUČAK: Unatoč standardnom brahiterapijskom pristupu, MR snimanje i slikovno 
vođenje tijekom brahiterapijske procedure promjenilo je raspored insercije katetera i strategiju 
planiranja zračenja. Klinički rad u brahiterapiji velikom brzinom doze u liječenju raka prostate 
upotrebom isključivo MR kao metode slikovnog navođenja je izvediv i siguran, no da bi bio 
opće prihvaćen potrebno ga je pojednostavniti.      
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10.  ABSTRACT IN ENGLISH  
 
PhD thesis: MRI guidance in high-dose-rate brachytherapy for prostate cancer 
PhD candidate: Jure Murgic, MD 
Year: 2017 
 
INTRODUCTION: MRI has been widely accepted as the best imaging modality for prostate 
cancer. However, there is lack of knowledge how MRI perform when applied in MRI-only 
workflow for catheter insertion and treatment planning in patients receiving standard-care high-
dose-rate (HDR) brachytherapy prior to external beam radiotherapy for prostate cancer. 
PATIENTS AND METHODS: Forty patients with intermediate or high-risk prostate cancer 
were enrolled on a prospective clinical trial approved by institution’s research ethics board. 
Multiparametric MR imaging with stereotactic navigation was used to guide insertion of 
brachytherapy catheters, followed by MRI-based treatment planning.   
RESULTS: Sixty-two implants were performed. Median catheter insertion + imaging time 
was 100 min, and overall anaesthesia time was 4.0 hours (range 2.1-6.9 hours). MRI at the time 
of brachytherapy re-staged 14 patients (35%) who were found to have a higher stage of disease. 
In 6 patients this translated in directed insertion of brachytherapy catheters outside of the 
prostate boundary (extracapsular disease (n=2) or seminal vesicle invasion (n=4)). Most 
patients (80%) had gross tumor visible on MRI, which influenced catheter insertion and 
treatment planning.  MRI depicted post-implant anatomic boundaries clearly, with the 
exception of the apical prostate which was blurred by blood after catheter insertion.  
Conventional dose planning objectives for PTV coverage (PTV V100>98%) and for the rectum 
(rectal V75<1.0 cc) were difficult to achieve, but toxicities were low (acute grade≥2 
genitourinary = 20%, late grade≥2 genitourinary = 15%, late grade ≥2 gastrointestinal = 
7%).Urethral trauma visualized on MRI led to 2 transient grade 3 events. 
CONCLUSION: Despite a standard-care treatment, MRI acquired throughout the procedure 
altered catheter insertion and dose-planning strategies. An MRI-only workflow is feasible and 
safe, but must be streamlined for broader acceptance.   
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Portions of this dissertation were previously published in the following manuscript: Murgic J, 
Chung P, Berlin A, Bayley A, Warde P, Catton C, et al. Lessons learned using an MRI-only 
workflow during HDR brachytherapy for prostate cancer. Brachytherapy. 2016; 15(2): 147-55. 
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